Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  01-JUN-2018A Phase 3, Multicenter, Randomized, Double-blind, Placebo-
controlled Study to Evaluate the Safety, Tolerability, and 
Immunogenicity of V114 When Administered Concomitantly with 
Influenza Vaccine in Healthy Adults 50 Years of Age or Older 
(PNEUFLU)
PRODUCT: V114 1
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Placebo -controlled 
Study  to Evaluate the Safety , Tolerability , and Immunogenicit y of V114 When Administered 
Concomitantly  with Influenza Vaccine in Healthy  Adul ts 50 Years of Age or Older (PNEU -
FLU)
Protocol Number: 021-01
Compound Number: V114
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889 -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND 14977
Approval Date: 01-JUN -2018 
  04Y38Y 
  05FQSH
PRODUCT: V114 2
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
Title:Date 
  04Y38Y 
  05FQSH
PRODUCT: V114 3
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
PROTOCOL AMENDMENT S UMMARY OF CHANGES 
Amendment: 01
Overall Rationale for the Amendments:
The primary  purpose of this amendment is to remove the collection of medical device incidents from the protocol (removal of S ection 
6.1.1, Section 8.4.8, and Appendix 4). The implementation of the FDA guidance for reporting events related to co mbination products 
has been delay ed until January  2020. Therefore, the current protocol is not within the scope of medical device reporting requ irements. 
Other clarifications and editorial revisions were also made as shown in the Summary  of Changes Table b elow .
Summary of Changes Table:
Section # and Name Description of Change  Brief Rationale  
2.2.1  V114 and Pneumococcal Disease Licensure dates for Prevnar 13™ were 
added to the third paragraph.
Revisions were made in the fourth 
paragraph to better align with the cited 
literature.Revisions made for accuracy .
5.2  Exclusion Criteria The number of exclusion criterion 23 has 
been corrected to 22.Correction of a t ypographical error .
6.1.1  Medical Devices
8.4.8   Medical Device Incidents (Including 
Malfunctions)
10.4  Appendix 4: Medical Device Incidents: 
Definition and Procedures for Recording, 
Evaluating, Follow -up, and ReportingSections removed. The implementation of the FDA 
guidance for reporting events related to 
combination products has been d elayed 
until January  2020. Therefore, the 
current protocol is not within the scope 
of medical device reporting 
requirements. 
  04Y38Y 
  05FQSH
PRODUCT: V114 4
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Section # and Name Description of Change  Brief Rationale  
6.5  Concomitant Therapy Concomitant corticosteroid rules were 
updated to align with other protocols in the 
V114 program.Updates necessary  for program 
consistency .
8.1.10   Telephone Contact Questio nnaire
1.3  Schedule of Activities (SoA)The text in Section 8.1.10 was revised as 
follows:
Original : All participants to collect 
additional information based on a will be 
contacted b y telephone at Month 7 to 
complete the Telephone Contact 
Questionnaire provided by the Sponsor.  
Data to be reported from on this discussion 
questionnaire will include SAEs and/or an y 
updates to previously  reported safet y 
information.
Revised : Site personnel will contact study  
participants to collect additional 
information based on a Telephone Contact 
Questionnaire provided by the Sponsor.  
Data to be reported from this discussion 
will include SAEs and/or any  updates to 
previously  reported safety  information.
The revised text was also added to the 
SoA.Revisions were made to clarify  the 
process for administering the telephone 
contact questionnaire. 
  04Y38Y 
  05FQSH
PRODUCT: V114 5
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Section # and Name Description of Change  Brief Rationale  
8.4.1  Time Period and Frequency  for 
Collecting AE, SAE, and Other Reportable 
Safety  Event InformationThe follo wing text was deleted from the 
second paragraph in this section:
All AEs, SAEs, and other reportable safety  
events must be reported by  the investigator 
from the day  of allocation/randomization to 
the first vaccination and from the day  of 
each vaccination through 14 day s (42 day s 
for live attenuated vaccines) 
postvaccina tion.  SAEs must also be 
reported throughout the duration of the 
individual’s participation in the study , 
regardless of whether or not related to the 
Sponsor’s product.Live attenuated vaccines are not 
provided as part of the study .
8.5  Treatment of Over dose The definition of overdose was revised as 
follows:
Original : In this study , an overdose is any  
dose higher than 1 dose of an y individual 
study  vaccine during the individual’s 
participation in the study .
Revised : In this study , an overdose is the 
admin istration of more than 1 dose of an y 
individual study  vaccine in any  24-hour 
period.Revisions made for accuracy . 
  04Y38Y 
  05FQSH
PRODUCT: V114 6
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Section # and Name Description of Change  Brief Rationale  
9.6.2   Statistical Methods for Safet y 
Analy ses, Table 5Tier 2 safety  endpoint was revised as 
follows (changes in bold ):
“Any SAE and vaccine -related AE” was 
changed to “ Any vaccine -related SAE ”Table was revised to align with safet y 
analysis plan and text under Tier 2 
Events .
Throughout Editorial revisions Changes are minor and have not been 
summarized individually . 
  04Y38Y 
  05FQSH
PRODUCT: V114 7
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Table of Contents
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 3
1 PROTOCOL SUMMARY ............................................................................................ 14
1.1 Synopsis ................................................................................................................. 14
1.2 Schema .................................................................................................................. 19
1.3 Schedule of Activities (SoA) ................................................................................ 20
2 INTRODUCTION .......................................................................................................... 23
2.1 Study Rationale .................................................................................................... 23
2.2 Background .......................................................................................................... 24
2.2.1 V114 and Pneumococcal Disease ................................................................ 24
2.2.1.1 Influenza Disease ............................................................................... 25
2.2.2 Preclinical and Clinical Studies ................................................................... 25
2.2.3 Information on Other Study -related Therap y.............................................. 26
2.2.3.1 Seasonal Inactivated Quadrivalent Influenza Vaccine ...................... 26
2.3 Benefit/Risk Assessment ...................................................................................... 26
3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS ................................................. 27
4 STUDY DESIGN ............................................................................................................ 29
4.1 Overall Design ...................................................................................................... 29
4.2 Scientific Rationale for Study Design ................................................................ .30
4.2.1 Rationale for Endpoints ............................................................................... 30
4.2.1.1 Immunogenicit y Endpoints ................................................................ 30
4.2.1.1.1 Pneumococcal Immunogenicity Endpoints .............................. 30
4.2.1.1.2 Influenza Immunogenicity  Endpoints ...................................... 31
4.2.1.2 Safety  Endpoints ................................................................................ 31
4.2.1.3 Future Biomedical Research .............................................................. 32
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 32
4.3 Justification for Dose ........................................................................................... 32
4.4 Beginning and End of Study Definition ............................................................. 32
4.4.1 Clinical Criteria for Early Study Termination ............................................. 32
5 STUDY POPULATION ................................................................................................ 33
5.1 Inclusion Criteria ................................................................................................ .33
5.2 Exclusion Criteria ................................................................................................ 33
5.3 Lifestyle Considerations ...................................................................................... 35
5.4 Screen Failures ..................................................................................................... 35
5.5 Participant Replacement Strategy ...................................................................... 35
6 STUDY INTERVENTION ............................................................................................ 36 
  04Y38Y 
  05FQSH
PRODUCT: V114 8
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
6.1 Study Intervention(s) Administered ................................................................... 36
6.2 Preparation/Handling/Storage/Accountability ................................................. 38
6.2.1 Dose Preparation .......................................................................................... 38
6.2.2 Handling, Storage, and Accountability ........................................................ 38
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 38
6.3.1 Intervention Assignment.............................................................................. 38
6.3.2 Stratification ................................................................................................ .39
6.3.3 Blinding ........................................................................................................ 39
6.4 Study Intervention Compliance .......................................................................... 39
6.5 Concomitant Therapy .......................................................................................... 40
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 40
6.7 Intervention After the End of the Study ............................................................ 40
6.8 Clinical Supplies Disclosure ................................................................................ 41
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL ............................................................................................................ 41
7.1 Discontinuation of Study Intervention ............................................................... 41
7.2 Participant Withdrawal From the Study ........................................................... 42
7.3 Lost to Follow -up................................................................................................ .42
8 STUDY ASSESSMENTS AND PROC EDURES ........................................................ 43
8.1 Administrative and General Procedures ........................................................... 44
8.1.1 Informed Consent ......................................................................................... 44
8.1.1.1 General Informed Consent ................................................................ .44
8.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 45
8.1.1.3 Consent and Collection of Blood Samples for Optional Assay  
Development ...................................................................................... 45
8.1.2 Inclusion/Exclusion Criteria ........................................................................ 45
8.1.3 Participant Identification Card ..................................................................... 45
8.1.4 Medical History ........................................................................................... 45
8.1.5 Prior and Concomitant Medications Review ............................................... 46
8.1.5.1 Prior Medications ............................................................................... 46
8.1.5.2 Concomitant Medications .................................................................. 46
8.1.6 Assignment of Screening Number ............................................................... 46
8.1.7 Assignment of Treatment/Randomization Number ..................................... 46
8.1.8 Study  Intervention Administration .............................................................. 46
8.1.8.1 Timing of Dose Administration ......................................................... 47
8.1.9 Electronic Vaccination Report Card ............................................................ 47
8.1.10 Telephone Contact Quest ionnaire ................................................................ 48 
  04Y38Y 
  05FQSH
PRODUCT: V114 9
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
8.1.11 Discontinuation and Withdrawal ................................................................ .48
8.1.11.1 Withdrawal From Future Biomedical Research ................................ 48
8.1.12 Participant Blinding/Unblinding .................................................................. 49
8.1.13 Calibration of Equipment ............................................................................. 49
8.2 Immunogenicity Assessments ............................................................................. 50
8.2.1 Multiplex Opsonophagocytic Assay  (MOPA) ............................................. 50
8.2.2 Electrochemiluminescence (ECL) ............................................................... 50
8.2.3 Hemagglutination I nhibition (HAI) Assay .................................................. 51
8.3 Safety Assessments ............................................................................................... 51
8.3.1 Physical Examinations ................................................................................. 51
8.3.2 Pregnancy  Test ............................................................................................. 51
8.3.3 Body Temperature Measurement ................................................................ .52
8.3.4 Safety  Assessments and Use of the eVRC ................................................... 52
8.3.5 Clinical L aboratory  Assessments ................................................................ .52
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 53
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 53
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......55
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...55
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 55
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 55
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ 56
8.4.7 Events of Clinical I nterest (ECI s)................................................................ 56
8.5 Treatment of Overdose ........................................................................................ 56
8.6 Pharmacokinetics................................................................................................ .56
8.7 Pharmacodynamics .............................................................................................. 56
8.8 Future Biomedical Research Sample Collection ............................................... 56
8.9 Planned Genetic Analysis Sample Collection .................................................... 56
8.10 Optional Assay Development Blood Sample Collection ................................... 57
8.11 Biomarkers ........................................................................................................... 57
8.12 Medical Resource Utilization and Health Economics ....................................... 57
8.13 Visit Requirements ............................................................................................... 57
8.13.1 Screening ...................................................................................................... 57
8.13.2 Treatment Period/Vaccination Visit ............................................................ 57
8.13.3 Discontinued Participants Continuing to be Monitored in the Study .......... 57
9 STATISTICAL ANALYSIS PLAN ............................................................................. 58 
  04Y38Y 
  05FQSH
PRODUCT: V114 10
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
9.1 Statistical Analysis Plan Summary..................................................................... 58
9.2 Responsibility for Analyses/In -house Blinding ................................................. 60
9.3 Hypotheses/Estimation ........................................................................................ 60
9.4 Analysis Endpoints ............................................................................................... 60
9.4.1 Immunogenicit y Endpoints .......................................................................... 60
9.4.2 Safety  Endpoints .......................................................................................... 61
9.5 Analysis Populations ............................................................................................ 62
9.5.1 Immunogenicit y Analysis Populations ........................................................ 62
9.5.2 Safety Anal ysis Populations ........................................................................ 63
9.6 Statistical Methods ............................................................................................... 63
9.6.1 Statistical Methods for Immunogenicit y Anal yses...................................... 63
9.6.2 Statistical Methods for Safety Anal yses...................................................... 66
9.6.3 Demographic and Baseline Characteristics ................................................. 69
9.7 Interim Analyses .................................................................................................. 69
9.8 Multiplicity ........................................................................................................... 69
9.9 Sample Size and Power Calculations ................................................................ .70
9.9.1 Sample Size an d Power for I mmunogenicity  Analy ses............................... 70
9.9.2 Sample Size and Power for Safet y Anal yses............................................... 70
9.10 Subgroup Analyses ............................................................................................... 71
9.11 Compliance (Medication Adherence) ................................................................ .71
9.12 Extent of Exposure ............................................................................................... 71
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ..................................................................................................... 72
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........ 72
10.1.1 Code of Conduct for Clinical Trials ............................................................. 72
10.1.2 Financial Disclosure ..................................................................................... 74
10.1.3 Data Protection ............................................................................................. 74
10.1.3.1 Confidentiality  of Data ...................................................................... 75
10.1.3.2 Confidentiality  of Participant Records ............................................... 75
10.1.3.3 Confidentiality  of IRB/IEC I nformation ............................................ 75
10.1.4 Committees Structure ................................................................................... 75
10.1.4.1 Scientific Advisory  Committee .......................................................... 75
10.1.4.2 Executive Oversight Committee ........................................................ 75
10.1.4.3 External Data Monitoring Committee ............................................... 76
10.1.5 Publication Policy ........................................................................................ 76
10.1.6 Compliance with Study  Registration and Results Posting Requirements ...76
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 77
10.1.8 Data Qualit y Assurance ............................................................................... 77 
  04Y38Y 
  05FQSH
PRODUCT: V114 11
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
10.1.9 Source Documents ....................................................................................... 78
10.1.10 Study  and Site Closure ................................................................................. 78
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 79
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 80
10.3.1 Definition of AE .......................................................................................... 80
10.3.2 Definition of SAE ........................................................................................ 81
10.3.3 Additional Events Reported ......................................................................... 82
10.3.4 Recording AE and SAE ............................................................................... 82
10.3.5 Reporting of AE, SAE, and Other Reportable Safety  Events to the 
Sponsor ........................................................................................................ 87
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ........................................... 89
10.5 Appendix 5: Contraceptive Guidance and Preg nancy Testing ........................ 90
10.5.1 Definitions .................................................................................................... 90
10.5.2 Contraception Requirements ........................................................................ 90
10.5.3 Pregnancy  Testing ........................................................................................ 92
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 93
10.7 Appendix 7: Country -specific Requirements .................................................... 98
10.8 Appendix 8: Abbreviations ................................................................................. 99
11 REFERENCES............................................................................................................. 101 
  04Y38Y 
  05FQSH
PRODUCT: V114 12
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
LIST OF TABLES
Table 1 Study  Interventions .......................................................................................... 37
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by Sample Types ...44
Table 3 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safet y Events ................................................................................. 54
Table 4 Analy sis Strategy  for Immunogenicit y Variables ............................................ 65
Table 5 Analy sis Strategy for Safety  Parameters Following Any  Vaccination ............ 67
Table 6 Differences in Incidence of AE Rates between the 2 Vaccination Groups 
That Can be Detected With an ~80% Probability  (Assuming 2 -sided 5% 
alpha level with 600 Participants in each Group) ............................................ 71
Table 7 Protocol -Required Safet y Laboratory  Assessments ......................................... 79
Table 8 Contraceptive Methods .................................................................................... 91 
  04Y38Y 
  05FQSH
PRODUCT: V114 13
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
LIST OF FIGURES
Figure 1 V114 -021 Study  Design ............................................................................. 19 
  04Y38Y 
  05FQSH
PRODUCT: V114 14
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Placebo -controlled 
Study  to Evaluate the Safety , Tolerability , and Immunogenicit y of V114 When Administered 
Concomitantly  with Influenza Vaccine in Healthy  Adults 50 Years of Age or Older (PNEU -
FLU)
Short Title: Safet y and Immunogenicit y of V114 Administered Concomitantly with 
Influenza Vaccine
Acronym: PNEUmococcal Conjugate Vaccine Trials : V114 -021(PNEU –FLU)
Hypotheses, Objectives ,and Endpoints :
The following objectives and endpoints will be evaluated in health y adults ≥50 y ears of age.
Primary  Objectives Primary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of V114 and quadrivalent 
influenza vaccine (QIV) when administered 
concomitantly  compared with V114 and QIV 
when administered nonconcomitantly  with 
respect to the proportion of participants with 
adverse events (AEs).Following an y vaccination:
-Solicited injection -site AEs from Day  1 
through Day  5postvaccination 
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination 
-Vaccine -related serious adverse events 
(SAEs) from Day  1 through Month 7
-Objective: To compare the serot ype-
specific opsonophagocy tic activity  (OPA) 
Geometric Mean T iters (GMTs) at 30 days 
postvaccination with V114 administered 
concomitantly  with QIV versus V114 
administered nonconcomitantly  with QIV. 
Hypothesis (H1): V114 administered 
concomitantly  with QIV is noninferior to 
V114 administered nonconcomitantly with 
QIV as measured b y seroty pe-specific OPA 
GMTs at 30 day s postvaccination with V114. 
(thestatistical criterion for noninferiorit y 
requires the lower bound of the 2 -sided 95% 
confidence interval [CI ] of the OPA GMT 
ratio [concomitant/nonconcomitant] to be
greater than 0.50)-Seroty pe-specific OPA responses for the 15 
seroty pes in V114 at 30 day s postvaccination 
with V114 
  04Y38Y 
  05FQSH
PRODUCT: V114 15
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
-Objective: To compare the strain -specific 
hemagglutination inhibition (HAI) GMTs at 
30 day s postvaccination with QIV 
administered con comitantly  with V114 
versus QIV administered nonconcomitantly  
with V114. 
Hypothesis (H2): QIVadministered 
concomitantly  with V114 is noninferior to 
QIV administered nonconcomitantly  with 
V114 as measured b y strain -specific HAI 
GMTs at 30 day s postvaccin ation with QIV. 
(thestatistical criterion for noninferiorit y 
requires the lower bound of the 2 -sided 95% 
CI of the HAI GMT ratio 
[concomitant/nonconcomitant] to be greater 
than 0.50)-Strain -specific HAI responses for the 
4strains in QIV at 30 days po stvaccination 
with QIV
Secondary  Objectives Secondary  Endpoints
-Objective: To evaluate the serot ype-specific 
Immunoglobulin G (IgG) Geometric Mean 
Concentrations (GMCs) at 30 day s 
postvaccination with V114 administered 
concomitantly  with QIV compared with 
V114 administered nonconcomitantly with 
QIV.-Seroty pe-specific IgG responses for the 15 
seroty pes in V114 at 30 day s postvaccination 
with V114
-Objective: Within each vaccination group, 
to evaluate the serot ype-specific Geometric 
Mean Fold Rises ( GMFRs) and proportions 
of participants with a ≥4-fold rise from 
baseline (prevaccination with V114) to 30 
days postvaccination with V114 for both 
OPA and IgG responses for participants 
administered V114 concomitantly  with QIV 
and participants administered V114 
nonconcomitantly  with QIV.-Seroty pe-specific OPA and IgG responses 
for the 15 serot ypes in V114 at 
prevaccination with V114 and 30 day s 
postvaccination with V114 
  04Y38Y 
  05FQSH
PRODUCT: V114 16
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
-Objective: Within each vaccination group, 
to evaluate the strain -specific 
(1) GMFRs from baseline (prevaccination 
with QIV) to 30 day s postvaccination with 
QIV, (2) proportions of participants with an 
HAI titer ≥1:40 at 30 days postvaccination 
with QIV, and (3) proportions of participants 
that seroconvert at 30 days postvaccination 
with QIV for participants administered QIV 
concomitantly  with V114 and participants 
administered QIV nonconcomitantly  with 
V114.-Strain -specific HAI responses for the 4 
strains in QIV at prevaccination with QI V 
and 30 day s postvaccination with QI V
Overall De sign:
Study  Phase Phase 3
Primary  Purpose Prevention
Indication Pneumococcal disease
Population Health y adults, 50 years of age or older
Study  Type Interventional
Intervention Model Parallel
This is a multi -sitestudy .
Type of Control Placebo
Study Blinding Double -blind
Masking Participant
Investigator
Estimated Duration o f Study The Sponsor estimates that the study will require 
approximately 9 to 10 months from the time the first 
participant signs the informed consent until the last 
participant’s last study -related telephone call or visit.
For purposes of analy sis and reporting, the overall study  
ends when the Sponsor receives the last serology  assay  
result. 
  04Y38Y 
  05FQSH
PRODUCT: V114 17
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Number of Participant s:
Approximately  1200 participants will be randomized, with approx imately  600 participants in 
each intervention group. 
Intervention Groups and Du ration :
Intervention 
Group s Intervention 
Group Name VaccineDose 
StrengthDose 
FrequencyRoute of 
Admin .Vaccination 
Regimen Use
Concomitant 
GroupV114 Refer to IB
Single DoseIM
Left armSingle Dose at 
Visit 1 (Day 1)Experimental
QIV Refer to 
product 
labelingSingle DoseIM
Right armSingle Dose at 
Visit 1 (Day 1)Experimental
Placebo NASingle DoseIM
Left armSingle Dose at 
Visit 2(Day 30)Experimental
Nonconcomitant 
GroupPlacebo NA
Single DoseIM
Left armSingle Dose at 
Visit 1 (Day 1)Experimental
QIV Refer to 
product 
labelingSingle DoseIM
Right armSingle Dose at 
Visit 1 (Day 1)Experimental
V114 Refer to IBSingle DoseIM
Left armSingle Dose at 
Visit 2 ( Day 30) Experimental
IB=Investigator’s Brochure; IM =intramuscular ; NA =not applicable ; QIV = quadrivalent influenza 
vaccine (seasonal inactivated) .
Total 
Number2 intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  7 months from 
the time the participant signs the Informed Consent Form (ICF) through the final 
contact.  
  04Y38Y 
  05FQSH
PRODUCT: V114 18
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 8. 
  04Y38Y 
  05FQSH
PRODUCT: V114 19
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
1.2 Schema
The study  design is depicted in Figure 1.
INCL/EXCL = Inclusion/Exclusion
PE = Physical Examination
eVRC = electronic Vaccination Report Card
Note: V114 and placebo are administered under double -blind conditions.
* Randomization isstratified byage and history of prior PNEUMOVAX™23 vaccination .
Figure 1V114 -021Study  Design
 
  04Y38Y 
  05FQSH
PRODUCT: V114 20
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
1.3 Schedule of Activities (SoA)
Study Period Intervention Follow -up
CommentsVisit Number : 1Telephone 
Contact 2Telephone 
Contact 3Telephone 
Contact
Scheduled Time: Day 1 Day 15 Day 30 Day 45 Day 60 Month 7
Visit Window:Day 15 to 
Day 19
after Visit 
1aDay 30 to
Day 44 
after Visit 
1aDay 15 to 
Day 19
after Visit 
2bDay 30to 
Day 44
after Visit 
2bDay 166to 
Day 194 
after Visit 
2b
Administrative and General Procedures
Screening Procedures
Informed Consent X Consent must be obtained before any study procedures.
Informed Consent for Optional 
Assay Development Blood Samples 
(Selected Study Sites Only)XConsent for optional assay development blood samples must be 
obtained before any of these samples are collected from a 
participant.
Informed Consent for Future 
Biomedical ResearchXConsent for future biomedical research samples must be obtained 
before the blood sample (DNA sample) is collected.
Assignment of Screening Number X
Inclusion/Exclusion Criteria X
Medical History
XThe participant’s medical history for the 5 years prior to study 
entry will be reviewed . History of tobacco use will also be 
collected for all participants.
Post-Enrollment Procedures
Assignment of Randomization 
NumberX
Participant Identification Card X
Prior/ Concomitant Medication and 
Nons tudy Vaccination ReviewX X X X X
V114 or Placebo Administration 
(Blinded) – Left ArmX XAt Visit 1 (Day 1), participants will receive a single dose of either 
(blinded) V114 or placebo; at Visit 2, participants will receive a 
single dose (blinded) of the other (ie, placebo or V114, 
respectively ).
Seasonal I nactivated Quadrivalent
Influenza Vaccine (QIV)
Administration (Open -label) –
Right ArmXAt Visit 1 (Day 1 ), participants will receive a single dose of QIV. 
  04Y38Y 
  05FQSH
PRODUCT: V114 21
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Study Period Intervention Follow -up
CommentsVisit Number : 1Telephone 
Contact 2Telephone 
Contact 3Telephone 
Contact
Scheduled Time: Day 1 Day 15 Day 30 Day 45 Day 60 Month 7
Visit Window:Day 15 to 
Day 19
after Visit 
1aDay 30 to
Day 44 
after Visit 
1aDay 15 to 
Day 19
after Visit 
2bDay 30to 
Day 44
after Visit 
2bDay 166to 
Day 194 
after Visit 
2b
Provide electronic Vaccinatio n 
Report Card (eVRC)XParticipants will be provided an eVRC at Visit 1 (Day 1) to record 
adverse events (AEs) and body temperature measurements. 
Instructions for using the eVRC will be reviewed with the 
participant.
Review eVRC Data with Participant X X X X
Collect eVRC from ParticipantX
Complete Telephone Contact 
Questionnaire
XSite personnel will contact study participants to collect additional 
information based on a Telephone Contact Questionnaire 
provided by the Sponsor. Data to be reported from this discussion 
will include s erious adverse events (SAEs) and/or any updates to 
previously reported safety information.
Safety Procedures
Complete Physical Examination XTo be performed by the investigator or medically qualified 
designee before vaccine is administered.
Directed Physical ExaminationXTo be performed by the investigator or medically qualified 
designee before vaccine is administered.
Pregnancy Test – if applicable
X XA pregnancy test consistent with local requirements (sensitive to 
at least 25 IU beta human chorionic gonadotropin, β-hCG) must 
be performed before administration of study vaccine in females 
who are of reproductive potential. Urine or serum tests can be 
used, and results must be negative before vaccination can occur.
Body Temperature Measurement 
Before Vaccination
X XEach participant's body temperature must be taken before 
vaccination. Participants who present with fever (oral or tympanic 
temperature ≥100.4°F [≥38.0°C]; axillary or temporal temperature 
≥99.4°F [≥37.4 °C]; or re ctaltemperature ≥101.4°F [≥38. 6°C]) 
will have the vaccination delayed until fever is resolved for 72 
hours.
30-Minute Postvaccination 
Observation PeriodX XTo be performed by blinded study site personnel only. 
  04Y38Y 
  05FQSH
PRODUCT: V114 22
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 01-JUN-2018
Study Period Intervention Follow -up
CommentsVisit Number : 1Telephone 
Contact 2Telephone 
Contact 3Telephone 
Contact
Scheduled Time: Day 1 Day 15 Day 30 Day 45 Day 60 Month 7
Visit Window:Day 15 to 
Day 19
after Visit 
1aDay 30 to
Day 44 
after Visit 
1aDay 15 to 
Day 19
after Visit 
2bDay 30to 
Day 44
after Visit 
2bDay 166to 
Day 194 
after Visit 
2b
AE Monitoring
X X X X X XAEs (serious and nonserious) are to be reported from Days 1 
through 14 following each vaccination. SAEs and deaths are to be 
reported throughout the duration of an individual’s study 
participation.
Immunogenicity Procedures
Serum for Pneumococcal 
Immunogenicity Assay ( Including 
Retention Serum )
X X XBlood samples must be collected before study vaccination when
applicable. After completion of opsonophagocytic activity (OPA)
and electrochemiluminescence (ECL) testing, serum samples will 
be stored to conduct any additional study -related testing as 
required by regulatory agencies or the Sponsor. Leftover sera 
from the study may be used for the development and/or validation 
of pneumococcal assays after completion of all study -related 
immunogenicity testing; this app lies only to sera received from 
randomized study participants who provided consent for future 
biomedical research .
Serum for Influenza 
Immunogenicity Assay (Including 
Retention Serum)
X XBlood samples must be collected before study vaccination where 
applicable. After completion of hemagglutination inhibition 
(HAI) testing, serum samples will be stored to conduct any 
additional study -related testing as required by regulatory agencies 
or the Sponsor. Leftover sera from the study may be used for the 
development and/or validation of pneumococcal assays after 
completion of all study -related immunogenicity testing; this 
applies only to sera received from randomized study participants 
who provided consent for future biomedical research .
Future Biomedical Research
Blood (DNA) for Future 
Biomedical ResearchXCollected from randomized participants who provided consent for 
future biomedical research (Section 8.8).
Assay Development Sample s
Serum for Optional Assay 
Development
(Selected Study Sites Only)X XCollected from randomized participants (target of a pproximately 
120 participants )who provided consent for Assay Development
Sample collection (Section 8.10) .
aWhen scheduling the Telephone Contact (Day 15) andVisit 2 (Day 30), the visit window “Day 1” is the date of Visit 1.
bWhen scheduling the Telephone Contact ( Day 45 ),Visit 3 (Day 60), and the Follow -up Telephone Contact (Month 7), the visit window “Day 1” is the date of Visit 2. 
  04Y38Y 
  05FQSH
PRODUCT: V114 23
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
2 INTRODUCTION
Merck Sharp & Dohme Corp. (MSD) is developing an investigational 15 -valent 
pneumococcal conjugate vaccine (PCV) (referred to as V114) for prevention of 
pneumococcal disease caused by  the serot ypes contained in the vaccine. V114 contains the 
13 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in the licensed 
vaccine Prevnar 13™ (pneumococcal 13 -valent conjugate vaccine [diphtheria CRM 197
protein], Wy eth Pharmaceuticals, a subsidiary  of Pfizer, Inc., Philadelphia, PA), plus 
2additional seroty pes (22F, 33F).
2.1 Study Ra tionale
This clinical study  willevaluate the safet y, tolerability , and immunogenicity  of V114 when 
administered concomitantly  with influenza vaccine in healthy participants ≥50 y ears of age .
This population is at elevated risk for pneumococcal disease and its associated morbidity  and 
mortality  [Drijkoningen, J. J 2014] [Matias, G., et al 2014] ,as well as the morbidity  and 
mortality  associated with influenz a infection. 
Pneumococcal pneumonia is a frequen t complication of influenza ,and simultaneous 
vaccination against both in at risk individuals has been shown to reduce rates of
hospitalization and mortality [Dominguez, A., et al 2013] [Zhang, Y. Y., et al 2016] . 
Concomitant administration of Prevnar 13 ™ and influenza vaccine results in robust immune 
responses for both pneumococcal and influenza antigens and can be a strategy  to increase 
vaccination rates [Gilchrist, S. A., et al 2012] [Frenck, R. W. Jr., et al 2012] [Schwarz, T. F., 
et al 2011] [Schwarz, T. F. 2013] .
Individuals in the target age population of this study may have received prior vaccination 
with P NEUMOVAX ™23,a pneumococcal vaccine containing the pol ysaccharides of 23 
pneumococcal serot ypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 
19A, 19F, 20, 22F, 23F, and 33F) and no adjuvant or carrier proteins. In the United States,
PNEUMOVAX ™23 is recommended for immunocompetent adults 19 to 64 y ears of age 
who have certain chronic medical conditions, including chronic heart disease, chronic liver 
disease, chronic lung disease, diabetes mellitus, smoking and alcohol abuse. In order to allow 
a comprehensive assessment of the concomitant administration of V114 and influenza 
vaccine in pneumococcal vaccine -naïve adults, this study  will enroll participants with and 
without prior PNEUMOVAX ™23 vaccination. In accordance with recommendation s
regarding the interval between vaccinations with PNEUMOVAX ™23 and a PCV , 
participants must have received PNEUMOVAX ™23at least 12 months prior to study  
enrollment. 
This study  is designed to evaluate the safet
y and tolerability of a single dose of V114 when 
administered concomitantly  and nonconcomitantly (ie, 30 day s after) with influenza vaccine . 
It will also evaluate whether V114 can be administered concomitantly  with influenza vaccine 
without impairing the antibody  response to the 15 seroty pescontain ed in V114 and to the 
4influenza viruses contained in the seasonal inactivated quadrivalent influenza vaccine  
  04Y38Y 
  05FQSH
PRODUCT: V114 24
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
(QIV). This study  will also contribute to the overall safety database and immunogenicit y data 
for V114 to support initial licensure in adults.
2.2 Background
2.2.1 V114 and Pneumococcal Disease
Refer to the Investigator’s Brochure (IB) for V114 for more detailed background, including 
information on pneumococcal disease burden.
Streptococcus pneumoniae is a significant cause of disease worldwide, with clini cal 
manifestations including pneumonia, meningitis, otitis media, sinusitis, and sepsis. Adults 
with comorbid conditions, in particular immunocompromised individuals, have a higher 
incidence of invasive pneumococcal disease ( IPD)morbidity  and mortality  inall age groups 
compared to adults without the comorbid conditions [Lexau, C. A., et al 2005] . 
Currently  licensed PCVs (eg, Prevnar™, Sy nflorix™, and Prevnar 13™) were first 
implemented in infant immunization p rograms in many countries worldwide. Prevnar™ was 
first licensed in 2000 and later replaced b y Prevnar 13™ in 2009 for the European Union and
in2010 for the United States . Although Prevnar 13™ is indicated for children and adults, 
Synflorix™ is only  indicated for children up to 5 y ears of age. Widespread use of PCVs has 
reduced the burden of pneumococcal disease caused by the serot ypes contained in the 
vaccines in children who were targeted b y the vaccination programs and unvaccinated 
individuals from other age groups (herd protection) [Centers for Disease Control and 
Prevention 2008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 2007] [Pilishvili, Tamara, et 
al 2010] [L exau, C. A., et al 2005] [Metlay
, J. P., et al 2006] [Whitney , Cynthia G., et al 
2003] [Moore, M. R., et al 2015] [L epoutre, A., et al 2015] [Weiss, S., et al 2015] 
[Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et al 2015] [Jokinen, J., 
et al 2015] [Palmu, A. A., et al 2015] [Wagenvoort, G. H., et al 2016] . Prevnar 13™ was also 
shown to be efficacious against vaccine -type nonbacteremic pneumococcal pneumonia and 
IPD in adults ≥65 y ears of age [Bonten, M. J., et al 2015] . These study  results were the basis 
of the recommendation from the Advis ory Committee on I mmunization Practices for the 
sequential administration of Prevnar 13™ followed at least 12 months later by 
PNEUMOVAX™23 in adults ≥65years of age [Tomczy k, S., et al 2014] [Kobay ashi, M., et 
al 2015] .
Although cases of IPD have decreased following implementation of PCVs, an increase in 
IPD caused b y serotypes not covered b y currently  available vaccines has been observed. 
V114 contains 2 additional serot ypes (22F, 33F) compared with Prev nar13™. The selection 
of 22F and 33F was primarily based on epidemiological importance of these 2 additional 
seroty pes. Recent data from the United States suggest that 22F is the most common seroty pe 
not included in Prevnar 13™ in adults ≥18 y ears of age, causing 13% of I PD cases. Seroty pe 
33F is associated with an additional 5% of I PD cases [Moore, M. R., et al 2015] . Data from 
the United Kingdom also showed that ,in 2013/2014 ,22F and 33F are frequent serot ypes in 
adults ≥65 y ears of age, accounting for approximately  10% and 4% of I PD cases in that age 
group , respectively  [Waight, P. A., et al 2015] . Data from 2014 reported in the 2016 annual  
  04Y38Y 
  05FQSH
PRODUCT: V114 25
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
epidemiological report o n IPD by  the European Centre for Disease Prevention and Control 
showed that both serot ypes 22F and 33F are among the most common seroty pes causing IPD 
[European Centre for Disease Prevention and Control 2016] .
The serot ypes included in V114 will provide broad coverage of the leading serotypes 
associated with pneumococcal disease worldwide. V114 is designed to meet continuing 
medical and public health needs for PCVs globally, as well as to address the emergence o f 
pneumococcal disease caused by  serot ypes not contained in currently licensed PCVs. V114 is 
designed to offer broader seroty pe coverage than Prevnar 13™ against pneumococcal disease 
in both pediatric and adult populations.
2.2.1.1 Influenza Disease
Influenza occu rs annually , typicall y circulating in the United States in late fall through earl y 
spring, in epidemic outbreaks of vary ing severity . The majority  of influenza cases are not 
associated with an y significant complications . However, the risk for complications , such as 
pneumonia, hospitalization, and death are higher forindividuals ≥65 y ears of age, y oung 
children, and persons of any  age with certain underly ing health conditions [Grohskopf, L . A., 
et al 2016] . 
Annu al mean rates of hospitalizations due to influenza in the U nited States between 1993 and 
2008 were 63.5 per 100,000 person -years. The highest rates were observed in adults ≥65 
years of age (309 per 100,000 person -years)[Zhou, H., et al 2012] . In the United States
alone, influenza infection has been responsible for 3,000 to 49,000 deaths each season (from 
the 1976 -77 through the 2005 -06 seasons) [Centers for Disease Contr ol and Prevention 
(CDC) 2010] and 55,000 to 431,000 hospitalizations annually (from the 1979 -80 through 
2000 -01 seasons) [Thompson, W. W., et al 2004] . 
Influenza illness may be prevented through vaccination .Antibody  responses are often lower 
in individuals ≥65 y ears of age than in younger adults, and some studies have shown 
statistically  significant decline in titers in individuals ≥65 y ears of age during the first 6 
months postvaccination [Kunzel, W., et al 1996] [Song, J. Y., et al 2010] .While vaccine 
effectiveness can vary , recent studies showed that vaccination reduces the risk of influenza 
illness by  about 40% to60% among the overall population during seasons when most 
circulating influenza viruses are like the vaccine viruses [Grohskopf, L. A., et al 2015] . 
2.2.2 Preclinical and Clinical Studies
Refer to the IB for information on completed prec linical and clinical studies conducted with 
V114. 
  04Y38Y 
  05FQSH
PRODUCT: V114 26
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
2.2.3 Information on Other Study -related Therapy
2.2.3.1 Seasonal Inactivated Quadrivalent Influenza Vaccine
Refer to approved labeling for Fluarix Quadrivalent fordetailed background information on 
the QIVused in this study .
The QIVprotects against the influenza viruses that research indicates will be most common 
during the upcoming season , and include santigens from influenza A (H1N1) virus, influenza 
A (H3N2) virus, influenza B /Victoria virus, and influenza B/Yamagata virus . 
In the United States, annual influenza vaccination is recommended for all individuals ≥6 
months of age [Grohskopf, L . A., et al 2017] . Most countries in the Euro pean Union 
recomm end annual influenza vaccination for individuals at risk for influenza associated 
morbidity  and mortality , such as children, o lder adults, pregnant women andindividuals with 
chronic diseases , and for health care workers [ECDC 2017] .
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
intervention during participation, as clinical studies are designed to provide information 
about the safet y and effectiv eness of an investigational vaccine.
While the impact of concomitant administration of V114 and QIVon the immune response to 
both vaccines is unknown and will be evaluated in this study , participants in both vaccination 
groups are expected to be sufficien tly covered by  the QIVfor the 2018 /2019 influenza season
through participation in this stud ybased on the experience of concomitant administration of 
Prevnar 13™ and influenza vaccines [Frenck, R. W. Jr., et al 2012] [Schwarz, T. F., et al 
2011] [Schwarz, T. F. 2013] .
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompanyi ng IB and the Informed Consent Form (ICF). 
  04Y38Y 
  05FQSH
PRODUCT: V114 27
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS
The following objectives and endpoints will be evaluated in health y adults ≥50 y ears of age.
Objectives Endpoints
Primary
•Objective : To evaluate the safet y and 
tolerability  of V114 and quadrivalent 
influenza vaccine ( QIV)when 
administered concomitantly  compared 
with V114 and QIV when administered 
nonconcomitantly  with respect to the 
proportion of participants with adverse 
events (AEs) .Following an y vaccination:
•Solicited injection -site AEs from Day  1 
through Day 5 postvaccination
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination 
•Vaccine -related serious adverse events 
(SAEs )from Day  1 through Month 7
Objective :To compare the serot ype-
specific opsonophagocy tic activity  
(OPA )Geometric Mean T iters ( GMTs )at 
30 day s postvaccination with V114 
administered concomitantly with QIV
versus V114 administered 
nonconcomitantly  with QIV .
Hypothesis (H1):V114 administered 
concomitantly  with QIV is noninferior to 
V114 administered nonconcomitantly  
with QIV as measured b y serotype -
specific OPA GMTs at 30 days 
postvaccination with V114 .
(thestatistical criterion for noninferiority 
requires the lower bound of th e 2-sided 
95% confidence interval [ CI]of the OPA 
GMT ratio 
[concomitant/nonconcomitant ] to be 
greater than 0.50)•Seroty pe-specific OPA responses for the 
15 seroty pes in V114 at 30 day s 
postvaccination with V114 
  04Y38Y 
  05FQSH
PRODUCT: V114 28
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Objectives Endpoints
Objective :To compare the strain -
specific hemagglutination inhibition 
(HAI)GMTs at 30 day s postvaccination 
with QIV administered concomitantly  
with V114 versus QIV administered 
nonconcomitantly  with V114 . 
Hypothesis (H2):QIVadministered 
concomitantly  with V114 is noninferior 
to QIV administered nonconcomitantly  
with V114 as measured by  strain -specific 
HAI GMTs at 30 day s postvaccination 
with QIV.
(thestatistical criterion for noninferiority 
requires the lower bound of the 2-sided 
95% CI of the HAI GMT ratio 
[concomitant/nonconcom itant] to be 
greater than 0.50)•Strain -specific HAI responses for the 
4strains in QIV at 30 days 
postvaccination with QIV
Secondary
•Objective : To evaluate the serot ype-
specific Immunoglobulin G (IgG)
Geometric Mean Concentrations ( GMCs )
at 30 day s postvaccination with V114 
administered concomitantly  with QIV 
compared with V114 administered
nonconcomitantly  with QIV.•Seroty pe-specific IgG responses for the 
15 seroty pes in V114 at 30 day s 
postvaccination with V114
•Objective : Within each vaccination 
group, to evaluate the seroty pe-specific 
Geometric Mean Fold Rise s (GMFRs )
and proportions of participants with a ≥4-
fold rise from baseline (prevaccination 
with V114) to 30 day s postvaccination
with V114 for both OPA and IgG 
responses for participants administered 
V114 concomitantly  with QIV and
participants administered V114 
nonconcomitantly  with QIV.•Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in V114 at 
prevaccination with V1 14 and 30 day s 
postvaccination with V114 
  04Y38Y 
  05FQSH
PRODUCT: V114 29
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Objectives Endpoints
•Objective: Within each vaccination 
group , to evaluate the strain -specific 
(1)GMFRs from baseline
(prevaccination with QIV) to 30 day s 
postvaccination with QIV, ( 2) 
proportion sof participants with an HAI 
titer ≥1:40 at 30 day s postvaccination 
with QIV , and (3) proportions of 
participants that seroconvert at 30 day s 
postvaccination with QIV for participants 
administered QIV concomitantly  with 
V114 and participants administered QIV 
nonconcomitantly  with V114 .•Strain -specific HAI responses for the 4 
strains in QIV at prevaccination with 
QIV and 30 day s postvaccination with 
QIV
4 S TUDY DESIGN
4.1 Overall Design
Approximately  1200participant s will be randomly assigned in a 1:1 ratio to receive either 
V114 with concomitant QIVor V114 with nonconcomitant QIV. Randomization will be 
stratified by  age (50 to 64 y ears, 65 to 74 y ears, and 75 y ears or older ;at least 50% of the 
participants will be 65 y ears of age or older) and by history  of prior PNEUMOVAX™23 
vaccina tion (y es and no ; at least 50% of participants are to bePNEUMOVAX™23 -naïve ).
Participant s enrolled in the concomitant group will receive V114 (blinded) in the left arm and 
QIV(open label) in the right arm on Day  1,and then will receive placebo (blinded) in the left
arm 30 day s later at Visit 2 (Day  30). 
Participant s enrolled in the nonconcomitant group will receive placebo (blinded) in the left
arm and QIV(open label) in the right arm on Day  1,and then will receive V114 (blinded) in 
the leftarm 30 da ys later at Visit 2 (Day  30).
Participants will be followed for local and s ystemic AEs through Day  14following each 
vaccination. Information for SAEs and deaths, regardless of whether the events are 
considered to be vaccine -related b y the investigator, will be collected from the time consent 
is signed through completion of participation in the study . An external Data Monitoring 
Committee (DMC) will conduct a periodic review of safet y and tolerability data for the adult 
V114 Phase 3 program. A description of the structure, function, and guidelines for decision -
making b y the DMC, along with the timing and c ontent of the safet y reviews will be outlined 
in the DMC charter. Information regarding the composition of the DMC is provided in 
Appendix 1. 
  04Y38Y 
  05FQSH
PRODUCT: V114 30
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Blood samples for immunogenicity  assay s will be drawn immediately before the first V114 
or placebo vaccination and the QIVvaccination at Visit 1 ( Day 1), before vaccination at Visit 
2 (Day 30), and at Visit 3 (Day  60).
After completion of OPA , electrochemiluminescence (ECL ), and HAI testing, serum samples 
will be stored to conduct any  additional study -related testing as required by  regulatory  
agencies or the Sponsor. Leftover sera from the study  may  be used for the development 
and/or validation of pneumococcal assay s after completion of all study -related 
immunogenicity testing; this applies only to sera received from randomized study  
participants who provided consent for future biomedical research .
Adult participant s at selected study  sites who consent (target of approximately  120 
participants ) will have 2 optional additional blood samples drawn (50 mL at each of Visit s1 
and 3 ) to support further development, validation ,and performance of anti -pneumococcal 
antibody  assay s.
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
This study  is conducted in a population (health y adults ≥50 y ears of age) at elevated risk for 
pneumococcal andinfluenza disease and associated morbidi ty and mortality  [Drijkoningen, J. 
J 2014] . 
The concomitant and nonconcomitant administration of V114 and QIVin this study  allows 
for meaningful comparisons of safet y, tolerability, and immunogenicit ybetween the 2 
administration ty pes.
In order to demonstrate that concomitant administration of V114 and QIVdoes not adversely  
affect the antibod y response to or safet y profile of either vaccine, concomitant and 
nonconcomitant administration groups are being generated in this study  through the use of a 
placebo to V114 . A saline placebo is being used to maintain blinded vaccine administration 
on Day  1and Day  30.Both groups of randomized participants will receive V114 in the study .
4.2.1 Rationale for Endpoints
4.2.1.1 Immunogenicity Endpoints
4.2.1.1.1 Pneumococcal Immunogenicity Endpoints
Sera from participants will be used to measure vaccine -induced, serot ype-specific OPA and 
IgG responses for all 15 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F ,23F, 
33F) inclu ded in V114 using the Multiplexed Opsonophagocy tic Assay  (MOPA) assay  and 
pneumococcal electrochemiluminescence (PnECL) assay . 
  04Y38Y 
  05FQSH
PRODUCT: V114 31
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Several studies have shown a positive correlation between serot ype-specific IgG antibody  
concentrations and OPA titers in childre n and adults [Centers for Disease Control and 
Prevention 2010] [Anttila, M., et al 1999] [Romero -Steiner, S., et al 1997] . OPA assesses 
levels of functional antibodies capable of opsonizing pneumoc occal capsular poly saccharides 
for presentation to phagocy tic cells for engulfment and subsequent killing, and therefore is 
considered an important immunologic surrogate for protection against I PD in adults. It is 
noted that threshold values that correlate with protection in adults have not been defined for 
either assay .
Details on the immunogenicity  endpoints evaluated in this study  can be found in Section 
9.4.1 .
4.2.1.1.2 Influenza Immunogenicity Endpoints
Antibodies that block the binding of the hemagglutinin anti gen of the influenza virus to host 
receptors contribute to natural or vaccine -induced immunity  to a homologous or related 
influenza virus and are generall y considered to be correlates of protective immunity against 
influenza [Zakay -Rones, Z. 2010] [ Reber, A. 2013] . The HAI assay detects antibodies that 
bind around the globular head of the hemagglutinin molecule, inhibiting the interaction of the 
virus with host cells. I t has been demonstrated that serum HAI titers are inversel y correlated 
with the frequency  of clinical influenza in vaccinated individ uals. However, no defined 
serum antibody  threshold exists and the relationship between HAI responses and protection is 
influenced b y preexisting immunity  and age[Reber, A. 2013] .
HAI responses are part of the criteria that regulatory agencies use for the evaluation and the 
licensure of influenza vaccines [Food and Dr ug Administration (CDER ) 2007] [European 
Medicines Agency  2016] , with p ostvaccination GMTs, seroconversion and seroprotection 
rates as recommended primary  endpoints. 
4.2.1.2 Safety Endpoints
The safet y endpoints evaluated in this study  were selected based on the product’s safet y 
profile demonstrated in previous studies, published data from marketed PCVs, and feedback 
received from regulatory  agencies during product development. The electronic Vaccination 
Report Card (eVRC) used to record AEs during the postvaccination periods, as defined in 
Section 8.1.9, was structured as recommended in the final US Food and Drug Administration 
Patient Reported Outcome Guidance [U.S. Food and Drug Administration 2009] . 
Details on the safet y endpoints evaluated in this study  can be found in Section 8.3.4 and 
Section 9.4.2.
Details on AEs, including definitions and reporting requirements, can be found in 
Appendix 3. 
  04Y38Y 
  05FQSH
PRODUCT: V114 32
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
4.2.1.3 Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on whi ch specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol ( as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the cor rect time. The 
details of this future biomedical r esearch substudy  are presented in Appendix 6.
4.2.2 Rationale for the Use of Comparator/Placebo
Placebo is used in this study  in order to maintain blinding to the concomitant and 
nonconcomitant group assignment . The placebo is sterile saline for injection. 
4.3 Justification for Dose
The dosing regimen of V114 is similar to that used in previous adult V114 clinical studies in 
which 1 dose has resulted in a robust immune response (refer to the V114 IB for more 
detailed information on dose selection ).
The dose of QIVfor use in this study  isthe approved dose.
4.4 Beginning and End of Study Definition
The overall study  begins when the first participant signs the ICF. The overall study  ends 
when the last participant completes the last study -related telephone -call or visit, withdraws 
from the study , or is lost to follow -up (ie, the participant is unable to be contacted b y the 
investigator).
For purposes of analy sis and reporting, the overall study  ends when the Sponsor receives the 
last serology  assay  result.
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study  early. 
  04Y38Y 
  05FQSH
PRODUCT: V114 33
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
5 STUDY POPULATION
Health y adult males and females ( ≥50 y ears of age) will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all o f the following criter ia appl y:
1.The participant is in good health. Any  underl ying chronic illness must be documented to 
be in stable condition.
Demographics
2.Participant is male or f emale ≥50 y ears of age .
Female Participants
3.A female participant is eligible to participate if sh e is not pregnant (Appendix 5), not 
breastfeeding, and at least 1 of th e following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 5.
OR
b.A WOCBP who agrees to use 1 of the contraceptive methods as defined in Appendix 
5during the treatment period and for at least 6 weeks after the last dose of study  
intervention .
Informed Consent
4.The participant provides written informed consent for the stud y. 
The participant may  also provide consent for future biomedi cal res earch and/or Assay  
Development Sample collection . However, the participant may  participate in the main 
study  without participating in future biomedical research or Assay  Development Sample 
collection .
5.2 Exclusion Criteria
Participants are excluded from the s tudy if any  of the following criteria apply :
Medical Conditions
1.History  of IPD (positive blood culture, positive cerebrospinal fluid culture, or positive 
culture at another sterile site) or known history  of other culture -positive pneumococcal 
disease withi n 3 y ears before Visit 1 (Day  1).
2.Known hy persensitivity  to any  component of pneumococcal pol ysaccharide vaccine, 
PCV , or any  diphtheria toxoid -containing vaccine . 
  04Y38Y 
  05FQSH
PRODUCT: V114 34
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
3.Known hy persensitivity  to any  component of influenza vaccines , including egg protein, 
or following a previous dose of an y influenza vaccine.
4.Known or suspected impairment of immunological function including, but not limited to, 
a history  of congenital or acquired immunodeficiency, documented HIV infection, 
functional or anatomic asplenia, or h istory  of autoimmune disease (including but not 
limited to the autoimmune conditions outlined in the Investigator Trial File Binder for 
this study ).
5.Has experienced Guillain -Barrésyndrome within 6 weeks of receiving a previous 
influenza vaccination.
6.Coag ulation disorder contraindicating intramuscular vaccinations.
7.*Recent febrile illness (defined as oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary  or temporal temperature ≥99.4°F [≥37.4 °C]; or re ctal temperature ≥101.4°F 
[≥38.6°C]) or received an tibiotic therapy  for an y acute illness occurring within 72 hours 
before receipt of study  vaccine.
8.History of malignancy  ≤5 years prior to signing informed consent, except for adequatel y 
treated basal cell or squamous cell skin cancer or in situ cervical ca ncer.
9.A WOCBP who has a positive urine or serum pregnancy  test before the first vaccination 
at Visit 1 (Day  1). 
Prior/Concomitant Therapy
10.Prior administration of an y PCV (eg, Prevnar 13™ )or is expected to receive an y 
pneumococcal vaccine during the study  outside of the protocol .
11.Prior administration of PNEUMOVAX™23 ≤12 month sbefore Visit 1. 
Note: individuals who received PNEUMOVAX™23 >12 month sprior to Visit 1 are 
eligible for this study . 
12.Previous receipt of influenza vaccine during the 201 8/2019 flu season or expected to
receive an y influenza vaccine during the stud y outside of the protocol.
13.Received s ystemic corticosteroids ( ≥20 mg/day prednisone equivalent ) for ≥14 
consecutive day s and has not completed intervention at least 30 day s before study  entry . 
14.Received s ystemic corticosteroids exceeding ph ysiologic replacement doses 
(approximately  5 mg/da y prednisone equivalent) within 14 days before vaccination . 
(Note: Topical, ophthalmic, intra -articular or soft -tissue [eg, bursa, tendon steroid
injections], and inhaled/nebulized steroids are permitted).
15.Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat 
cancer or other conditions, and interventions associated with organ or bone marrow 
transplantation, or autoimm une disease . 
16.*Received an y non -live vaccine within the 14 day s before receipt of any  study  vaccine or 
is scheduled to receive any  non-live vaccine within 30 day s following receipt of any  
study  vaccine. 
  04Y38Y 
  05FQSH
PRODUCT: V114 35
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
17.*Received an y live vaccine within 30 days before rece ipt of any  study  vaccine or is 
scheduled to receive an y live vaccine within 30 days following receipt of any  study  
vaccine.
18.Received a blood transfusion or blood products, including immunoglobulin within the 6 
months before receipt of study  vaccine or is s cheduled to receive a blood transfusion or 
blood product within 30 day s of receipt of study  vaccine. Autologous blood transfusions 
are not considered an exclusion criterion.
Prior/Concurrent Clinical Study Experience
19.Is currently  participating in or has participated in an interventional clinical study  with an 
investigational compound or device within 2 months of participating in this current stud y.
Other Exclusions 
20.Is, at the time of signing informed consent, a user of recreational or illicit drugs or ha s 
had a recent history  (within the last y ear) of drug or alcohol abuse or dependence as 
assessed b y the stud y investigator .
21.Has history  or current evidence of any  condition, therap y, lab abnormalit y or other 
circumstance that might expose the participant t o risk by  participating in the study , 
confound the results of the study , or interfere with the participant’s participation for the 
full duration of the study .
22.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) w ho is investigational site or Sponsor staff directly  involved with this study .
For items with an asterisk (*), if the participant meets th ese exclusion criteria, the 
Day 1 Visit may be rescheduled for a time when these criteria are not met.
5.3 Lifestyle Cons iderations
No lifesty le restrictions are required .
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities . Minimal information includes demograp hy, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from the stud ywill not be replaced . 
  04Y38Y 
  05FQSH
PRODUCT: V114 36
PROTOCOL/AMENDMENT N O.:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
6 STUDY INTERVENT ION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
Clinical supplies (V114, placebo, and QIV) willbe packaged to support enrollment .Clinical 
supplies will be affixed with a clinical label in accordance with regulatory requirements.
6.1 Study Intervention(s) Administered 
  04Y38Y 
  05FQSH
PRODUCT: V114 37
PROTOCOL/AMENDMENT NO .:021-01
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
The study intervention s to be used in this study are outlined inTable 1.
Table 1 Study  Interventions
Arm Name Arm TypeIntervention 
NameTypeDose 
FormulationUnit Dose 
StrengthDosage 
LevelRoute of 
AdminVaccination 
RegimenUseIMP/
NIMPSourcing
Concomitant 
GroupExperimental V114 Biological/
VaccineSterile suspension 
(prefilled syringe)Refer to IB 0.5 mL IM
Left armSingle Dose at Visit 
1 (Day 1)Experimental IMP Central
Concomitant 
GroupExperimental QIVaBiological/
VaccineSterile solution 
(prefilled syringe)Refer to product 
labeling0.5 mL IM
Right armSingle Dose at Visit 
1 (Day 1)Experimental IMP Central
Concomitant 
GroupExperimental Placebo
(Sterile Saline)Biological/
VaccineAmpule N/A 0.5 mL IM
Left armSingle Dose at Visit 
2 (Day 30)Experimental IMP Central
Nonconcomitant 
GroupExperimental Placebo 
(Sterile Saline)Biological/
VaccineAmpule N/A 0.5 mL IM
Left armSingle Dose at Visit 
1 (Day 1)Experimental IMP Central
Nonconcomitant 
GroupExperimental QIVaBiological/
VaccineSterile solution 
(prefilled syringe)Refer to product 
labeling0.5 mL IM
Right armSingle Dose at Visit 
1 (Day 1)Experimental IMP Central
Nonconcomitant 
GroupExperimental V114 Biological/
VaccineSterile suspension 
(prefilled syringe)Refer to IB 0.5 mL IM
Left armSingle Dose at Visit 
2 (Day 30)Experimental IMP Central
aFluarix Quadrivalent (Influenza Vaccine) 
Admin=administration; IB =Investigator’s Brochure; IM =intramuscular; IMP =investigational medicinal product ; NIMP =non-investigational medicinal 
produc t; QIV = quadrivalent influenza vaccine (seasonal inactivated) .
The definition of IMP and NIMP is based on guidance issued by the European Com mission. Regional and/or country differences of the definition of IMP/NIMP 
may exist. In these circumstances, local legislation is followed.
All supplies indicated in Table 1will be provided per the “Sourcing ”column depending upon local country  operational requirements. 
Every  attempt should be made to source these supplies from a single lot/batch number .
Refer to Section 8.1.8 for details regarding administration of the study  intervention. 
  04Y38Y 
  05FQSH
PRODUCT: V114 38
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
6.2 Preparation/Handling/Storage/Accountability
6.2.1 Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. T he rationale for selection of doses to be used 
in this study  is provided in Section 4.3. 
6.2.2 Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature c onditions have been 
maintained during transit for all study intervention received, and an y discrepancies are 
reported and resolved before use of the stud y intervention .
Only  participants enrolled in the study  may  receive study  intervention , and only  author ized 
site staff may  supply  or administer study  intervention . All study  intervention s must be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to t he investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, a
nd final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where loc al discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locall y purc hased product (if applicable) as per local guidelines unless otherwise 
instructed by  the Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, dist ribution, and usage of stud y 
intervention s in accordance with the protocol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Treatment allocation/randomization will occur centrally using an interactive response 
technology  (IRT) s ystem. There are 2study  intervention arms. Participants will be assigned 
randomly  in a 1:1ratio to receive either V114 concomitantly with QIVor V114 
nonconcomitantly with QIV. 
  04Y38Y 
  05FQSH
PRODUCT: V114 39
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
6.3.2 Stratification
Treatment allocation/randomization will be stratified according to the following factors at 
time of randomization :
Age (50 to 64 y ears of age , 65 to 74 y ears of age , and ≥75 y ears of age ).At least 50% 
of the partic ipants will be ≥65 y ears of age.
History of prior PNEUMOVAX™23 vaccination (Yes andNo). At least 50% of 
participants will be PNEUMOVAX™23 -naïve. 
6.3.3 Blinding
A double -blinding technique will be used. V114and placebo will be prepared and/or 
dispensed b y an unblinded pharmacist or unblinded qualified study  site personnel. The 
participant and the investigator who is involved in the clinical evaluation of the participants 
will remain blinded to the group assignments.
Because the V114 and placebo have a dif ferent appearance, a member of the study site staff 
will be unblinded for the purpose sof receiving, maintaining, preparing and/or dispensing, 
and administering the sestudy vaccine s.QIVwill also be prepared and/or dispensed and 
administered b y unblinded study  site staff for consistency  even though it will be provided 
open -label in this study . In order to avoid bias, the unblinded study person nelwill have no 
further contact with study participants for any study -related procedures/assessments after 
administration of study  vaccines, which includes all safety  follow up procedures . 
Additionally , blinded site personnel will not be present in the exam room when study  
vaccines are administered. Contact between participants and unblinded study personnel after 
vaccination administration is strictly  prohibited . 
Blinded site personnel will be responsible for all safet y and immunogenicity follow -up 
procedures after vaccine administration .
An unblinde d Clinical Research Associate will monitor vaccine accountability  at the study  
site. All other Sponsor personnel or delegate(s) and Merck Research Laboratories employ ees 
directly  involved with the conduct of this study  will remain blinded to the participan t-level 
intervention assignment.
See Section 8.1.1 2for a description of the method of unblinding a participant during the 
study  should such action be warranted.
6.4 Study Intervention Compliance
Interruptions from the protocol specified plan for V114 or placebo and QIV vaccination sat 
Visit 1 (Day  1) and placebo or V114 vaccination at Visit 2 (Day 30)require consultation 
between the investigator and the Sponsor and written documentation of the collaborative 
decision on participant management. 
  04Y38Y 
  05FQSH
PRODUCT: V114 40
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
6.5 Concomitant Therapy
Medications or vaccinatio ns specificall y prohibited in the exclusion criteria are not allowed
during time periods specified by  this protocol for that medication or vaccination . If there is a 
clinical indication for any medication or vaccination spe cificall y prohibited, di scontinuation 
from study  intervention may be required. The investigator should discuss any  questions 
regarding this with the Sponsor Clinical Director . The final decision on any supportive 
therap y or vaccination rests with the inves tigator and/or the participant ’s primary  physician. 
However, the decision to continue the participant on study  intervention requires the mutual 
agreement of the investigator, the Sponsor, and the participant.
Listed below (items 1 to 4) arespecific restri ctions for concomitant therapy  or vaccination 
during the course of the study : 
1.Any administration of a nonstudy  pneumococcal vaccine is prohibited during the 
study .
2.Live and non -live vaccines may  only  be administered prior to or following the receipt 
of study  vaccine according to the time frames specified in exclusion criteria 
(Section 5.2).
Vaccines should not be given within 30 days after receipt of stud y vaccine. 
Participants should not receive an influenza vaccine during the 2018/2019 flu season 
outside of the study .
3.Participants should not receive s ystemic corticosteroids ( ≥20 mg/day prednisone 
equivalent for ≥14 consecutive day s) starting from 30 day s prior to t hrough 30 day s 
following each stud y vaccination. Note: Topical, ophthalmic, intra -articular or soft -
tissue (eg, bursa, tendon steroid injections), and inhaled/nebulized steroids are 
permitted.
4.Participants should not receive s ystemic corticosteroids excee ding ph ysiologic 
replacement doses (prednisone equivalent dose >5 mg/day ) within 14 day s before any  
vaccination. Note: Topical, ophthalmic, intra -articular or soft -tissue (eg, bursa, tendon 
steroid injections), and inhaled/nebulized steroids are permitted.
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant management.
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification is allowed i n this study .
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y. 
  04Y38Y 
  05FQSH
PRODUCT: V114 41
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
6.8 Clinical Supplies Disclosure
This study  is blinded but supplies are provided open label; therefore, an unblinded 
pharmacist or unblinded qualified study  site personnel will be used to maintain the blinding 
of study  staff who are directly  involved in the clinical evaluation of participants in the study . 
Study  intervention identity  (name, strength, or potency ) is included in the label text; random 
code/disclosure envelopes or lists are not provided.
The emergency  unblinding call center will use the intervention /randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergency  
unblinding call center should only  be used in cases of emergency  (see Section 8.1. 12). In the 
event that the emergency unblinding call ce nter is not available for a given site in this study , 
the central electronic intervention allocation/randomization sy stem (IRT) should be used to 
unblind participants and to unmask study  intervention identity . The Sponsor will not provide 
random code/discl osure envelopes or lists with the clinical supplies.
S
ee Section 8.1.12for a description of the method of unblinding a participant during the 
study , should such action be warranted .
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL
7.1 Disconti nuation of Study Intervention
Discontinuation of study  intervention does not represent withdrawal from the study .
As certain data on clinical events bey ond study  intervention discontinuation may  be 
important to the study , they  must be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the protocol -specified vaccination s
will still continue to participa te in the study  as specified in Section 1.3 and Section 8.1 3.3, 
unless the participant withdraws consent (Section 7.2) .
Participants may  discontinue study  intervention at any  time for any  reason or be d iscontinued 
from the study  intervention at the discretion of the investigator should an y untoward effect 
occur. In addition, a participant may  be discontinued from study  intervention by  the 
investigator or the Sponsor if study intervention is inappropriate, the stud y plan is violated, or 
for administra tive and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation are provided in Section 8.1.11 .
A participant must be discontinued from study intervention but continue to be monitored in 
the stu dy for an y of the following reasons:
•The participant requests to discontinue study  intervention. 
  04Y38Y 
  05FQSH
PRODUCT: V114 42
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
•The participant has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or Sponsor, placed the participant at unnecessar y risk from continued 
administration of study intervention.
•The participant has a confirmed positive urine or serum pregnancy  test before vaccination 
with placebo /V114 vaccine at Visit 2(Day  30).
For participants who are discontinued from study  interventi onbut continue to be monitored 
in the study , see Section 1.3 and Section 8.13.3for those procedures to be completed at each 
specified visit.
Discontinuation from study  intervention is “permanent.” Once a participant is discontinued, 
he/she shall not be a llowed to restart study  intervention .
7.2 Participant Withdrawal From the Study
A participant must be withdrawn from the study  if the participant withdraws consent from the 
study .
If a participant withdraws from the study, they will no longer receive stud y treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific details regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.11 .The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact the participant 
are outlined in Section 7.3.
7.3 Lost to Follow -u
p
If a participant fails to return to the clinic for a required study  visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
•The site must attempt to contact the participant and reschedule the missed visit. I f the 
participant is contacted, the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact with the participant 
at each missed visit (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally  equivalent methods). These contact attempts should be 
documented in the participant’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit f or the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines. 
  04Y38Y 
  05FQSH
PRODUCT: V114 43
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
8 STUDY ASSESSMENTS AN D PROCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
appropriatel y qualified or trained staff. Delegatio n of study  site personnel responsibilities 
will be documented in the Investigator Study File Binder (or equivalent).
•All study -related medical decisions must be made by  an investigator who is a qualified 
physician . 
•All screening evaluations must be comple ted and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as appl icable.
•Additional evaluations/testing may  be deemed necessary  by the investigator and or the 
Sponsor for reasons related to participant safet y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulations.
Table 2shows the approximate blood volumes drawn b y study visit and by sample type. The 
maximum amount of blood collected from each participant at each stud y visit for 
immunogenicit y assessments will not exceed 40mL and the total amount of blood for the 
entire study  will not exceed 1 20 mL . For those participants that consent to future biomedical 
research , an additional blood sample of approximately  8.5 mL will be taken. For those at 
selected stud y sites who consent to provide optional assay  development blood sam ples(target 
of approximately  120 participants) , additional blood sample sof approximately  50mL will be 
taken at Visit 1 (Day 1) and Visit 3 (Day  60).
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples. 
  04Y38Y 
  05FQSH
PRODUCT: V114 44
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by Sample Types
Study VisitVisit 1
Day 1Visit 2
Day 30Visit 3
Day 60
Blood parameter Approximate Blood Volume (mL)
Serum for immunogenicity assays (including retention serum) 40 mL 40 mL 40 mL
Blood (DNA) for future biomedical research 8.5 mL N/A N/A
Optional assay development blood samplesa50 mL N/A 50 mL
Expected totala48.5 mL 40 mL 40 mL
aOptional assay development blood samples will be obtained from a total of only approximately 120 
participants and therefore the volumes associated with these samples are not included in the Expected total 
values. For participants who consent to provide op tional assay development blood samples, the total blood 
volumes drawn will be approximately 98.5 mL, 40 mL, and 90 mL at Visit 1, Visit 2, and Visit 3, respectively.
DNA = deoxyribonucleic acid
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant prior to participating in a clinical 
study or future biomedical r esearch . If there are changes to the part icipant’s status during the 
study  (eg, health or age of majority  requirements), the investigator or medically  qualified 
designee must ensure the appropriate consent is in place.
8.1.1.1 General Informed Consent
Consent must be documented by  the participant’s dated signature on a consent form along 
with the dated signature of the person conducting the consent discussion.
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study .
The initial I CF, any  subsequent r evised written ICF, and an y written information provided to 
the participant must receive the Institutional Review Board/Independent Ethics Committee’s 
(IRB/IEC’s )approval/favorable opinion in advance of use. The participant should be 
informed in a timely  manner if new information becomes available that may be relevant to 
the participant’s willingness to continue participation in the study . The communication of 
this information will be provided and documented via a revised consent form or addendum to 
the or iginal consent form that captures the participant’s dated signature.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level. 
  04Y38Y 
  05FQSH
PRODUCT: V114 45
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
The informed consent will adhere to IRB/IEC requirements, applicable law s and regulations, 
and Sponsor requirements .
8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically quali fied designee will explain the future biomedical r esearch 
consent to the participant, answer all of his/her q uestions, and obtain written informed 
consent before performin g any procedure related to the future biomedical research sub study . 
A cop y of the informed consent will be given to the participant.
8.1.1.3 Consent and Collection of Blood Samples for Optional Assay De velopment
At selected stud y sites (target of approximately  120 participants) , the investigator or 
medically  qualified designee will explain the consent for the optional assay development 
blood samples to the participant, answer all of his/her questions, and obtain written informed 
consent before performing an y procedure related to the optional assay  development blood 
samples collection . A copy  of the informed con sent will be given t o the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator who is a qualified 
physician to ensure that the participant qualifies for the study .
If the participant meets any  of the e xclusion criteria with an asterisk (*), Visit 1 (Day 1) may  
be rescheduled for a time when these criteria are not met.
8.1.3 Participant Identification Ca rd
All participants will be given a participant identification card ide ntify ing them as participants 
in a research stud y. The card will contain study site contact information (including direct 
telephone numbers) to be used in the event of an emergency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately  after 
the participant provides written informed consent. At the time of intervention
allocation/randomization, site personnel will add the intervention/randomization number to 
the participant identification card .
The participant identification card also contains contact information for the emergency 
unblinding call center so that a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical Histo ry
A medical history  will be obtained by  the investigator or qualified designee before 
vaccination at Visit 1 (Day 1). The participant’s medical history for the 5 years prior to Visit 
1 (Day  1) will be obtained to ensure that the participant s atisfies the inclusion and exclusion 
criteria of the study . History  of tobacco usewill also be collected for all participants . 
  04Y38Y 
  05FQSH
PRODUCT: V114 46
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
8.1.5 Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qualified designee will review and record prior vaccinations and 
medication staken b y the participant within 30 days before the first dose of study vaccine at 
Visit 1 (Day 1).
Any history  of prior PNEUMOVAX™ 23 vaccination will be reviewed and recorded.
8.1.5.2 Concomitant Medications
The investigator or qualif ied designee will record medication, if an y, taken by the participant 
during the stud y.
New and/or concomitant medications taken after Visit 1 (Day  1) and nonstudy  vaccines 
received since Visit 1 will be recorded with the eVRC as specified in Section 8.3.4 .
8.1.6 Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomization.Each participant 
will be assigned onl y 1 screening number . Screening numbers must not be re -used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit. Specific details on the screening/rescreening visit 
requir ements are provided in Section 8.13.1.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single partici pant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
V114 or placebo will be administered at Visit 1 (Day  1) and placebo or V114 will be 
administered at Visit 2 (Day  30). QIVwill be administered at Visit 1 (Day  1).
V114 should be removed from the refrigerator no more than 1 hour before vaccination. The 
time of removal and time of vaccination should be documented in the participant’s chart. 
  04Y38Y 
  05FQSH
PRODUCT: V114 47
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Unblinded study  personnel not otherwise involved in the conduct of th e study  will prepare 
and administer V114 or placebo and QIV at the study  site. QIV will be administered open -
label .
Prior to administration of V114, the unblinded pharmacist should shake the product 
vigorousl y to obtain a homogenous white suspension. If wh ite-colored insoluble particle 
appears, the unblinded pharmacist should use rapid, horizontal hand shaking for 5 to 10 
seconds while holding the sy ringe in between the thumb and index finger until complete 
resuspension. This action should be repeated, as necessary . If appearance is otherwise, the 
vaccine should not be administered. The vaccine should not be used if the vaccine cannot be 
resuspended.
For QIV, s tudy personnel should follow the preparation and administration instructions for 
Fluarix Quadrival ent (influenza vaccine) as specified in the product label . 
Study vaccine will be administered as a single 0.5 -mL intramuscular injection in the deltoid 
region of the participant’s arm . Vaccination information, such as Component I dentification 
Number and t ime of vaccination, must be recorded on the appropriate electronic case report 
form ( eCRF )per the Data Entry  Guidelines.
All safet y and immunogenicity assessments will be conducted b y blinded personnel, and the 
participant will be blinded to the interven tion (ie, V114 then placebo vs placebo then V114).
8.1.8.1 Timing of Dose Administration
Vaccinations may  be administered at any  time of day , and without regard to timing of meals. 
Each participant's body  temperature must be taken before each vaccine administrati on. 
Individuals who present with fever ( oral or t ympanic temperature ≥100.4°F [≥38.0°C] ; 
axillary  or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature ≥101.4°F 
[≥38.6°C] ) will have the vaccination delayed until fever is resolved for at least 72hours.
The collection of blood samples and administration of pregnancy tests (if applicable) must be 
done before each vaccine administration. 
All participants will be observed for 30 minutes after each vaccination for any immediate 
reactions. This observ ation must be performed by blinded site personnel for all study  
vaccines (Section 1.3 and Section 6.3. 3).
8.1.9 Electronic Vaccination Report Card
The eVRC was developed to be administered electronically  via a hand -held device. This item 
was structured as recommended in the final Food and Drug Administration Patient Reported 
Outcome Guidance [U.S. Food and Drug Administration 2009] . The investigator or delegate 
will train the participant in the use of the eVRC at Visit 1 (Day  1).  
  04Y38Y 
  05FQSH
PRODUCT: V114 48
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Temperatures, injection -site reactions, vaccine -specific complaints, other complaints or 
illnesses, and concomitant medications or vaccinations will be recorded on the eVRC as 
described in Section 1.3 and Section 8.3. 4. The investigato r or delegate will review the data 
captured on the eVRC with the participant at Telephone Contact (Day  15), Visit 2 (Day  30), 
Telephone Contact (Day  45), and Visit 3 (Day 60).
For the AEs outlined above, the investigator will use the information provided b y the 
participant both on the eVRC, and verball y at the time of eVRC review, to apply the 
appropriate assessment of intensity  and toxicity  as described in Appendix 3.
8.1.10 Telephone Contact Questionnaire
Site personnel will contact study  participants to collect additional information based on a 
Telephone Contact Questionnaire provided b y the Sponsor . Data to be reported from this 
discussion will include SAEs and /orany updates to previously  reported safety  information .
8.1.11 Discontinuation and Withdrawal
Participants who discontinue study intervention prior to completion of the protocol -specified
vaccination sshould be encouraged to continue to be followed for all remaining stud y visits.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study  visit (Visit 3 [Day 60]) should be performed if the participant 
can attend during the Day 30 window or the Day 60 window. If the participant withdraws at 
any other time, the Month 7 Telephone Contact acti vities should be performed (at the time of 
withdrawal). An y AEs that are present at the time of withdrawal should be followed in 
accordance with the safety requirements outlined in Section 8.4 .
8.1.11.1 Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomedical r esearch. Participants may  
withdraw consent at an y time by  contacting the principal investigator for the main study . If 
medical records for the main study  are still available, the investigator will contact the 
Sponsor using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently ,the participant's consent for future biomedical r esearch will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It i s the 
responsibility  of the investigator to inform the participant of completion of withdrawal. An y 
analyses in progress at the time of request for withdrawal or alread y performed prior to the 
request being received by the Sponsor will continue to be used as part of the overall research 
study  data and results. No new analys es would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y reg ulatory  authorities to retain the main study  records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawa l cannot be processed .  
  04Y38Y 
  05FQSH
PRODUCT: V114 49
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
8.1.12 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the inv estigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the drug used by  a participant and /orthe dosage 
administered , he/she will contact the emergency  unblinding call center by t elephone and 
make a request for eme rgency  unblinding. As requested by  the investigator or medicall y 
qualified designee the emergency  unblinding call center will provide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contacting the emergency  
unblinding call center to request unblinding of a participant’s treatment assignment, the 
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity /toxicity  grade of the AEs observed, the relation to study  intervention, the reason 
thereof , etc., in the medical chart. If it is not possible to record this assessment in the chart 
prior to the unblinding, the unblinding should not be delay ed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency  unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel may  beunblinded so that the appropriate follow -up medical care can be 
provided to the participant .
Participants whose treatment assignment has been unblinded by the investigator or medicall y 
qualified designee and/or nonstudy  treating ph ysician should continue to be monitored in the 
study .
Additionally , the investigator or medically  qualified designee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding call center is not av ailable for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that this is required for 
participant safety .
8.1.13 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and /ormaintained to ensure that the data ob tained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site. 
  04Y38Y 
  05FQSH
PRODUCT: V114 50
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG for serot ypes 
included in V114. These endpoints will be tested for all blood draws. Blood collection, 
storage and shipment instructions for serum samples will be provided in the 
operations/laboratory  manual. 
The MOPA will be used for measuring OPA GMTs. Opsonization of pneumococci for 
phagocy tosis is an important mechanism by  which antibodies to poly saccharides protect 
against disease in vivo. The OPA assay  is a useful tool for assessing the protective function 
of serot ype-specific antibodies and therefore the immunogeni city of pneumococcal vaccine 
formulations.
Measurement of serot ype-specific IgG will be measured using the PnECL  v2.0 assay  to 
assess the concentration of binding antibodies to capsular pol ysaccharide of S. pneumoniae 
for the serot ypes included in the stud y vaccines.
The HAI assay will be used to measure influenza vaccine -induced antibodies which inhibit 
hemagglutination. The HAI results reflect the degree ofhemagglutination inhibition .
8.2.1 Multiplex Opsonophagocytic Assay (MOPA)
The MOPA, developed and published by  Professor Moon Nahm (Director of the United 
States World Health Organization pneumococcal serology reference laboratory and National 
Institutes of Health pneumococcal reference laboratories), is a multiplexed OPA assay 
capable of measuring 4 serotypes at a time, against a total of 16 serot ypes of pneumococci 
[Burton, Robert L . and Nahm, Moon H. 2006] . The OPA is an antibod y-mediated killing 
assay  that measures the ability  of h uman serum to kill S. pneumoniae serot ypes with the help 
of complement and phagocytic effector cells. The ability  of the assay  to simultaneously  test 4 
seroty pes/run reduces the amount of serum needed for testing. The assay  readout is the 
opsonization index, which is the reciprocal of the highest dilution that gives ≥50% bacterial 
killing, as determined b y comparison to assay  background controls. MSD has developed and 
optimized the MOPA in a high throughput microcolony  platform. The MOPA assay  for all 
15 V1 14 serot ypes has undergone validation. The validation study evaluated various 
performance parameters of the assay  including precision, relative accuracy/dilutional 
linearity , and specificity . The validation results were evaluated against prespecified 
accep tance criteria for each of the parameters.
8.2.2 Electrochemiluminescence (ECL)
MSD has developed and optimized a multiplex, ECL -based detection method for the 
quantitation of IgG serotype -specific antibodies to the 15 pneumococcal poly saccharide 
seroty pes conta ined in V114. The PnECL  v2.0 assay  is based on the Meso -Scale Discovery  
technology , which employ s disposable multi -spot microtiter plates. The benefits of the ECL 
multiplex technology  over the prior enzyme-linked immunosorbent assay methodology  
include spe ed, equivalent or better sensitivity , increased dy namic range, the ability  to 
multiplex, and reduction in required serum sample and reagent volumes. The measurement of  
  04Y38Y 
  05FQSH
PRODUCT: V114 51
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
immune responses to the 15 seroty pes included in V114 is performed using an assay  format
consisting of 2 groups of 7 and 8 serot ypes each. The PnECL  v2.0 assay  for all 15 seroty pes 
has undergone validation. The validation study evaluated various performance parameters of 
the assay  including precision, ruggedness, relative accuracy, dilutional linearity , selectivity , 
and specificit y. The validation results were evaluated against pre -specified acceptance 
criteria for each of the parameters.
8.2.3 Hemagglutin ation Inhibition (HAI) Assay
The HAI assay  is based on the World Health Organization (WHO) established method as 
described in the WHO Manual for the Laboratory  Diagnosis and Virological Surveillance of 
Influenza [WHO Global Influenza Surveilla nce Network 2011] .The HAI assay  relies on the 
tendency  of influenza virus to bind to red blood cells (RBCs) ,causing them to agglutinate. It 
is a traditional me thod to measure vaccin e-induced antibod ies to hemagglutinin that bind to
the hemagglutinin molecul e, thereby inhibiting hemagglutination. The HAI test is generall y 
performed using microtiter plates. In a first step, nonspecific inhibitors of hemagglutination 
that occur naturall y in sera are removed prior to testing . Seriall y diluted serum is then mixed 
with standardized quantities of hemagglutinin antigens compatible with the strains included 
in the seasonal vaccine formulation . After addition of RBCs, the degree of inhibition of 
agglutination compared to strain -specific reference sera is being assessed. The HAI titer is 
the inverse of the highest dilution of serum exhibiting complete inhibition of 
hemagglutination . 
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. Th e total amount of blood to be drawn over the course of the study (from prestud y 
to poststudy  visits ), including approximate blood/tissue volumes drawn b y visit and by  
sample ty pe per particip ant, can be found in Section 8 .
Planned time points for all safet y assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete ph ysical examination will be conducted by an investigator or medically  qualified 
designee (consistent with local requirements) before vaccination at Visit 1 (Day 1). A 
directed ph ysical examination will be conducted by an investigator or medically  qualified 
designee (consistent with local requirements) before vaccination at Visit 2 (Day  30). 
Investigators should pay  special attention to clinical signs related to previous illnesses.
8.3.2 Pregnancy Test
A pregnancy  test consistent with local requirements (sensitive to at least 25 IU beta human 
chorionic gonadotropin [β -hCG]) must be performed before vaccination at Visit 1 (Day  1) 
and Vi sit 2 (Day  30) in WOCBP as described in Section 1.3. Urine or serum tests can be 
used, and results must be negative before vaccination can occur . 
  04Y38Y 
  05FQSH
PRODUCT: V114 52
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
8.3.3 Body Temperature Measurement
Each participant's body  temperature must be taken before vaccination ,as describe d in 
Section 1.3.
Oral bod y temperatures will also be documented by participants using their eVRC during the 
eVRC -specified postvaccination follow -up period (Section 8.3.4).
For this study , any  oral or ty mpanic temperature ≥100.4°F (≥38.0°C), axillary  or temporal 
temperature ≥99.4°F (≥37.4°C), or rectal temperature ≥101.4°F (≥38.6°C) will be considered 
an AE of fever. All fevers must be reported Day  1 through Day  14, unless the fever is a 
symptom of another reported AE.
8.3.4 Safety Assessment sand Use of the eVR C
All participants will be observed for 30 minutes after each vaccination for any immediate 
reactions. If an y immediate AEs are observed during this period, the time at which the event 
occurred within this timeframe, as well as the event itself, any concom itant medications that 
were administered, and resolution of the event, must be recorded on the appropriate eCRF.
Participants will use the eVRC (Section 8.1.9) to document the following information:
Oral bod y temperatures measured Day 1 (day of vaccination) through Day 5 
postvaccination;
Solicited injection -site AEs (redness/ery thema, swelling, and tenderness/pain) Day  1 
through Day  5 postvaccination;
Solicited sy stemic AEs (muscle pain/my algia, joint pain/arthralgia, headache, and 
tiredness/fati gue) Day  1 through Day  14 postvaccination;
Any other injection -site or sy stemic AEs Day 1 through Day  14 postvaccination; and
Concomitant medications and nonstudy  vaccinations Day  1 to Day  14 postvaccination
8.3.5 Clinical Laboratory Assessments
•Refer to Appendi x 2 for the list of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency .
•All protocol -required laboratory  assessments, as defined in Appendix 2 , must be 
conducted in accordance with the laboratory  manual and the SoA .
•If laboratory  values from nonprotocol specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in study  participant management or are 
considered clinically  significant by  the investigator (eg, SAE or AE or dose 
modificat ion), then the results must be recorded in the appropriate CRF (eg, SL AB). 
  04Y38Y 
  05FQSH
PRODUCT: V114 53
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
•For an y laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 30 to 44 days after the last dose of stud y intervention , 
every  attempt should be made to perform repeat assessments until the values return to 
normal or baseline or if a new baseline is established as determined b y the investigator .
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs) ,and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  the participant 
(or, when appropriate, b y a caregiver orsurrogate).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that me et the definition of an AE or SAE, as well as other reportable safet y events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event In formation
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must be reported by  the investigator if they  cause the 
participant to be excluded from the study , or are the result of a protocol -specified 
intervention, including but not limited to washout or discontinuation of usual therap y, diet, 
placebo treatment, or a procedure.
All AEs, SAEs, and other reportable safety events must be reported b y the investigator from 
the day  of allocation/randomization to the first vaccination and from the day of each 
vaccination through 14 day s postvaccination.  SAEs must also be reported throughout the 
duration of the individual’s participation in the study, regardless of whether or not related to 
the Sponsor’s product.
Additionally , any SAE brought to the attention of an investigator at an y time outside of the 
time period specified in the previous paragraph also must be reported immediatel y to the 
Sponsor if the event is either:
1. A death that occurs prior to the participant completing the study .
OR
2.An SAE that is considered by  an investigator who is a qualified ph ysician to be 
vaccine related. 
  04Y38Y 
  05FQSH
PRODUCT: V114 54
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Investigators are not obligated to activel y seek AE or SAE or other reportable safet y events 
in former study participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  parti cipation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3.
Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through Protoc ol-
Specified Follow -
up PeriodReporting Time Period:
After the Protocol 
Specified Follow -up 
PeriodTimefram e to 
Report Event 
and Follow -
up 
Information 
to Sponsor :
Nons erious Adverse 
Event Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
-any death until 
participant completion of 
study
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
interventio n
-causes exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin 24 
hours of 
learning of 
event
Events of Clinical 
InterestThere are no Events of Clinical I nterest for this study. Not 
applicable
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving 
placebo run -in or 
other run -in 
medication Report all Not required Within 5 
calendar days 
of learning of 
event 
  04Y38Y 
  05FQSH
PRODUCT: V114 55
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and nonleading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Sect ion 7.3). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safet y of participants and the 
safety of a stud y intervention under clinical investigation are met .
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. All 
AEs will be reported to regulatory  authorities, IRB/IECs, and in vestigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidelines for 
Good Clinical Practice [GCP] ).
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR s) acco rding to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from th e Sponsor will file it 
along with the IB and will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregna ncy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the stud y are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregn ancy  continues to term, the outcome 
(health of infant) must also be reported. 
  04Y38Y 
  05FQSH
PRODUCT: V114 56
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This is not applicable to this study .
8.4.7 Events of Clinical Interest (ECI s)
There are no events of clinical interest for this study .
8.5 Treatment of Overdose
In this stud y, an overdose is the administration of more than 1 dose of an y individual study  
vaccine in an y 24-hour period .
No specific information is available on the treatment of overdose.
Decisi ons regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Sponsor Clinical Director based on the clinical evaluation of the 
participant.
All reports of overdose must be reported b y the investigator within 5 calendar day s to the 
Sponsor either by electronic media or paper. Electronic reporting procedures can be found in 
the electronic data collection ( EDC )data entry  guidelines. Paper reporting procedures can be 
found in the Investigator Trial File Binder (or equivalent).
8.6 Pharmacokinetics
Pharmacokinetic parameters will not be evaluated in this study .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
•DNA for future research
•Leftover stud y serum after completion of immunogenicity testing stored for future 
research
8.9 Planned Genetic Analysis Sample Collection
Planned genetic a nalysis samples will not be evaluated in this study . 
  04Y38Y 
  05FQSH
PRODUCT: V114 57
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
8.10 Optional Assay Development Blood Sample Collection
Each participant enrolled at the selected stud y sites will be asked to provide optional assay  
development blood sample s until approximately  120 participant s have consented.
Each participant providing consent will have a 50 -mL sample of blood collected at Visit 1 
(Day  1)and Visit 3 (Day 60) (100mL total). These additional blood samples will be used to 
establish a proficien cy panel for a particular assay , which requires high -volume single -donor 
samples to monitor performance of the assay  over time .
Sample collection, storage, and shipment instructions for the optional assay development
blood samples will be provided in the o perations/laboratory  manual .
8.11 Biomarkers
Biomarkers are not evaluated in this study .
8.12 Medical Resource Utilization and Health Economics
Medical Resource U tilization and Health Economics are not evaluated in this study .
8.13 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
8.13.1 Screening
Screening procedures will be conducted at Visit 1 (Day  1) as outlined in Section 1.3.
8.13.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section 1.3.
8.13.3 Discontinued Participants Continuing to be Monitored in the Study
Aparticipant may discontinue from study  intervention (ie, vaccination) but continue to 
participate in subsequent protocol visits as outlined in Section 1.3, as long as the participant 
does not withdraw consent . Protocol -specified activities, including blood draws for 
immunogenicit y assessments and AE monitoring, should occur at these visits. 
  04Y38Y 
  05FQSH
PRODUCT: V114 58
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistica l analy sis strategy  and procedures for the study . If, after the 
study  has begun, but prior to unblinding, changes are made to hy potheses, or the statistical 
methods related to those hy potheses, then the protocol will be amended (consistent with I CH 
Guideli ne E-9). Changes to other nonconfirmatory anal yses made after the protocol has been 
finalized, but prior to unblinding/final database lock, will be documented in a Supplemental 
Statistical Analy sis Plan and referenced in the Clinical Study  Report (CSR) for the stud y. 
Post hoc exploratory  analy ses will be clearl y identified in the CSR.
9.1 Statistical Analysis Plan Summary
Key elements of the Statistical Analysis Plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12 .
Study Design Overview A Phase 3, Multicenter, Randomized, Double -Blind, Placebo -
Controlled Study to Evaluate the Safety, Tolerability, and 
Immunogenicity of V114 When Administered Concomitantly with 
Influenza Vaccine in Healthy Adults 50 Years of Age or Older (PNEU 
–FLU)
Intervention Assignment Participants will be randomly assigned in a 1:1 ratio to V114 w ith 
concomitant QIV or V114 w ith nonconcomitant QIV, respectively. 
Randomization will be stratified into 6 groups according to the
participant’s age (50 to 64 years, 65 to 74 years, and ≥75 years) and 
history of prior PNEUMOVAX™23 vaccination (Yes and No) at the 
time of randomization as described in Section 6.3.2.
Analysis Populations Immunogenicity : Per Protocol (PP)
Safety : All Pa rticipants as Treated (APaT)
Prim ary Endpoint(s) Immunogenicity :
Serotype -specific OPA GMT sat 30 days postvaccination with 
V114
Strain-specific HAI GMT sat 30 days postvaccination with QIV
Safety : 
Proportion of participants with solicited injection -siteAEs 
(redness/erythema, swelling, tenderness/pain ) from Day 1 through 
Day 5following any vaccination
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia, joint pain/arthralgia, headache, and 
tiredness/fatigue )from Day 1 through D ay 14 following any 
vaccination
Proportion of participants with vaccine -related SAEs from Day 1 
to Month 7
Key Secondary EndpointsSerotype -specific IgG GMC sat 30 days postvaccination with
V114 
  04Y38Y 
  05FQSH
PRODUCT: V114 59
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Statistical Methods for Key 
Immunogenicity AnalysesImmunogenicity analyses will be conducted for each of the 15 
pneumococcal serotypes in V114 and each of the 4 influenza strains in 
QIV separately. 
Theprimary objective (to compare the serotype -specific OPA GMTs 
at 30 days postvaccination with V114 betw een participants 
administered V114 concomitantly with QIV versus participants 
administered V114 nonconcomitantly with QIV) will be assessed via 
the following noninferiority hypotheses :
H0: GMT 1/GMT 2≤0.50versus 
H1: GMT 1/GMT 2>0.50
where GMT 1is the serotype -specific OPA GMT for the concomitant 
group and GMT 2is the serotype -specific OPA GMT for the 
nonconcomitant group. The primary objective (to compare the strain -
specific HAI GMTs at 30 days postvaccination with QIV betw een 
participants administered QIV concomitantly with V114 versus 
participants administered QIV nonconcomitantly) will be assessed via 
the following noninfer iority hypotheses:
H0: GMT 1/GMT 2≤0.50 versus 
H1: GMT 1/GMT 2>0.50
where GMT 1is the strain -specific HAI GMT for the concomitant 
group and GMT 2is the strain -specific HAI GMT for the 
nonconcomitant group. The serotype -specific OPA GMTs at 30 days 
postvaccination with V114 and strain -specific HAI GMTs at 30 days 
postvaccination with QIV will be compared betw een intervention 
groups separately. Comparisons will be made through the estimation of 
serotype -specific OPA GMT ratios for each of the 15 serotypes in 
V114 and strain -specific HAI GMT ratios for each of the 4 strains in 
QIV, resp ectively. Serotype -specific OPA GMT ratios and strain -
specific HAI GMT ratiosestimation, 95% CI s, and results from the
hypothesis test s(i.e., 1 -sided p -value s) will be calculated using a 
constrained longitudinal data analysis (cLDA )method utilizing data 
from both vaccination groups . Estimation of the serotype -specific IgG 
GMC ratio sand 95% CI swill be calculated using the cLDA method.
Statistical Methods for Key 
Safety AnalysesP-values (Tier 1 endpoints) and 95% CIs (Tier 1 and T ier 2 endpoints) 
will be provided for betw een-group differences in the percentage of 
participants with events; these analyses will be performed using the
unstratified Miettinen and Nurminen method [Miettinen, O. and 
Nurminen, M. 1985] .
Interim Analyses To support the periodic review of safety and tolerability data across the 
V114 Phase 3 program, an external unblinded statistician will provide 
unblinded interim safety summaries to an independent external DMC 
for their review. There are no plans to conduct an interim analysis of 
unblinded immunogenicity data in this study.
Multiplicity The overall success of the study requires demonstrating success on all 
15 pneumococcal serotypes and all 4 influenza strains i ncluded in the 
primary immunogenicity hypotheses. This approach controls the 1 -
sided type -I error rate at 0.025, and no multiplicity adjustment is
required. 
  04Y38Y 
  05FQSH
PRODUCT: V114 60
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Sample Size and Power Immunogenicity :
This study will randomize approximately 600 participants into the 
concomitant group and 600 participants into the nonconcomitant group 
and has approximately 87% pow er overall for demonstrating 
noninfer iority of OPA GMT ratio for the 15 pneumococcal serotyp es 
included in V114 and noninfer iority of HAI GMT ratio for the4 
influenza strains in QIV at an overall 1-sided 2.5% alpha -level. 
Safety : 
Section 9.9.2 provides information about the ability of this study to 
estimate the incidence of AEs within and betw een the concomitant and 
nonconcomitant group .
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor .
This study  will be conducted as a double -blind study  under in -house blinding procedures. 
The official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study  intervention assignment. Randomization will be implemented using an IRT.
Blinding issues related to the planned interim analyses are described in Section 9.7
9.3 Hypotheses/Estimation
Objectives and h ypotheses of the study  are stated in Section 3 .
9.4 Analysis Endpoints
Immunogenicit y and safety analy sis endpoints that will be evaluated for within -and/or
between -intervention differences are listed below.
9.4.1 Immunogenicity Endpoints
A description of immunogenicity assessments is contained in Section 8.2. 
The primary  immunogenicity  analy sis endpoint s include: 
Seroty pe-specific OPA GMT s
at 30 day s postvaccination with V114
Strain- specific HAI GMT sat 30 day s postvaccination with QIV 
  04Y38Y 
  05FQSH
PRODUCT: V114 61
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
The secondary  immunogenicity  analysis endpoints include:
Seroty pe-specific IgG GMC s at 30 day s postvaccination with V114
Seroty pe-specific GMFR sand proportion sof participants with a 4-fold rise from 
baseline (prevaccination with V114) to 30 day s postvaccination with V114 for both 
OPA and IgG responses
Strain- specific HAI GMFR s from baseline (prevaccination with QIV) to 30 day s 
postvaccination with QIV
Strain -specific p roportion sof participants with a HAI tite r ≥1:40 at 30 days 
postvaccination with QIV
Strain- specific propo rtions of participants that seroconvert at 30 day s postvaccination 
with QIVfor HAI responses . Seroconversion for HAI responses is defined as 
achieving either (1) a 4-fold rise in HAI titer from baseline (prevaccination with QIV)
to 30 day spostvaccination with QIV among participants who are seropositive at
baseline (HAI titer ≥1:10) or (2) a HAI titer of ≥1:40 at 30 day s postvaccination with 
QIV among participants who are seronegative at baseline (HAI titer < 1:10)
9.4.2 Safety Endpoints
A description of safet y measures is contained in Sections 8.3 and 8.4. The anal ysis of safety  
results is described in Section 9.6.2.
The safet y analysis endpoints include :
Proportion of participants with solicited injection -site AEs (redness/ery thema, 
swelling, tenderness/pain )from Day 1 through Day 5 following an y vaccination
Proportion of participants with solicited systemic AEs (muscle pain/m yalgia, joint 
pain/arthralgia, headache, and tiredness/fatigue )from Day 1 through Day 14
following an y vaccination
Proportion sof participants with the broad AE categories consisting of an y AE, a 
vaccine -related AE, a SAE, a death, an AE which is both vaccine -related and serious, 
an AE which lead sto discontinuation
Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day 1 through Day  5 following an y 
vaccination 
  04Y38Y 
  05FQSH
PRODUCT: V114 62
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
9.5 Analysis Populations
9.5.1 Immunogenicity Analysis Populations
The Per -Protocol (PP) population will serve as the primary  population for the anal ysis of 
immunogenicit y data in this study .The PP population consists of all randomized participants 
withoutdeviations from the protocol that may  substantially  affect the re sults of t he 
immunogenicit y endpoint s. Potential d eviations that may result in the exclusion of a 
participant from the PP population for all immunogenicity  analyses include:
Failure to receive an y study  vaccine at Visit 1(Day  1)
Failure to receive correct clinical material as per randomiz ation schedule at Visit 1 
(Day  1)(ie, participants who were cross -treated )
Receipt of a prohibited medication or prohibited vaccine prior to study  vaccination
Additional deviations that may  result in the exclusion of a pa rticipant from the PP population 
for specific immunogenicity  anal yses (depending on the time point) include:
Failure to recei ve an y study  vaccine at Visit 2(Day  30)
Failure to receive correct clinical material as per randomiz ation schedu le at Visit 2
(Day 30)
Receipt of a prohibited medication or prohibited vaccine prior to a blood sample 
collection 
Collection of ablood sample outside of the pre -specified window (as described in 
Section 1.3)
The final determination on protocol deviations that impact the immunogenicity  anal ysis, and 
thereb y the composition of the PPpopulation, will be made prior to the final unblinding of 
the database. Participant s will be included in the vaccination group to which they  are 
randomized for the analysis of immunogenicity data using the PPpopulation .
A supportive anal ysis using the Full Anal ysis Set (FAS) population will also be performed 
for the primary  immunogenicity  endpoint. The FAS population consi sts of all randomized 
participants who received at least 1study  vaccination and have at least 1serology result. 
Participants will be included in the vaccination group to which they  are randomized for the 
analysis of immunogenicity  data using the FAS popu lation.  
  04Y38Y 
  05FQSH
PRODUCT: V114 63
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
9.5.2 Safety Analysis Populations
Safety  anal yses will be conducted in the All Participants as Treated (APaT) population, 
which consists of all randomized participants who received at least 1dose of study  
vaccination. Participants will be included in the group corresponding to the study  vaccination 
they actuall y received for the anal ysis of safety  data using the APaT population . This will be 
the group to which they  are randomized except for p articipants who take incorrect study  
vaccination; such parti cipants will be included in the group corresponding to the study  
vaccination actually  received. If a participant received the same vaccine at Visit 1 and Visit 2 
due to the incorrect medication administration, resulting in the administration of 2doses of 
V114 or 2doses of placebo , this participant’s data w ould be excluded from APaT and would 
be summarized separately .
At least 1temperature measurement obtained subsequent to study  intervention is required for 
inclusion in the analy sis of temperature. 
9.6 Statistical Methods
Statistical testing and inference for immunogenicity  and safet y anal yses are described in 
Section 9.6.1 and Section 9.6.2, respectively. Unless otherwise stated, all statistical tests will 
be conducted at the α=0.05 (2 -sided) level . Section9.6.3 describes how demographic and 
baseline characteristics will be summarized.
9.6.1 Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the primary and secondary 
immunogenicit y objectives.
Immunogenicit y anal yses will be conducted for each of the 15 pneumococcal serot ypesin 
V114 and each of the 4 influenza strains in QIV separately .
The primary  objective (to compare the serot ype-specific OPA GMTs at 30 day s 
postvaccination with V114 between participants administered V114 concomitantly  with QIV 
versus participants administered V114 nonconcomitantly  with QIV) will be assessed via the 
following noninfer iority  hypotheses:
H0: GM T1/GM T2≤0.50 versus 
H1: GM T1/GM T2>0.50,
where GM T1is the serotype -specific OPA GMTfor the concomitant group and GM T2is the 
seroty pe-specific OPA GMTfor the nonconcomitant group. A ratio of 0.5 0corresponds to a 
2.0-fold decrease of OPA GMT in the concomitant group as compared with the 
nonconcomitant group . This same statistical criterion has been previously  applied to evaluate 
Prevnar 13™ when administered concomitantl y with influenza vaccine [Frenck, R. W. Jr., et 
al 2012] [Schwarz, T. F., et al 2011 ] [Schwarz, T. F. 2013] . Rejecting the null hy pothesis 
(H0) at the 1- sided α=0.025 level corresponds to the lower bound of the 2 -sided 95% CI  on 
the GMT ratio ( concomitant/ nonconcomitant ) being >0.50 and would lead to the conclusion  
  04Y38Y 
  05FQSH
PRODUCT: V114 64
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
that the OPA respon ses in the concomitant group are noninfer ior to the nonconcomitant 
group for the 15 pneumococcal se rotypes. 
The primary  objective (to compare the strain -specific HAI GMTs at 30 day s postvaccination 
with QIV between participants administered QIV concomitan tly with V114 versus 
participants administered QIV nonconcomitantly ) will be assessed via the following 
noninfer iority  hypotheses:
H0: GMT 1/GMT 2≤0.50 versus 
H1: GMT 1/GMT 2>0.50, 
where GMT 1is the strain -specific HAI GMT for the concomitant group and GMT 2is the 
strain -specific HAI GMT for the nonconcomitant group. A ratio of 0. 50 corresponds to a 2.0-
fold decrease of HAI GMT in the concomitant group as compared with the nonconcomitant 
group . This same statistical criterion has been previously  applied to evaluate influenza 
vaccine when administered concomitantl y with Prevnar 13™ [Frenck, R. W. Jr ., et al 2012] 
[Schwarz, T. F., et al 2011] [Schwarz, T. F. 2013] [U.S. Department of Health & Human
Services 2018] . Rejecting the null h ypothesis (H 0) at the 1- sided α=0.025 level corresponds 
to the lower bound of the 2 -sided 95% CI on the GMT ratio ( concomitant/ nonconcomitant ) 
being >0. 50 and would lead to the conclusion that the influenza HAI responses in the 
concomitant group arenoninfer ior to the nonconcomitant group for the 4 influenza strains.
To address the 2 primary immunogenicit y objectives, the serot ype-specific OPA GMT sat 30 
days postvaccination with V114 and strain -specific HAI GMT sat 30 day s postvaccination 
with QIV will be compared between intervention groups separatel y. Comparisons will be 
made through the estimation of serot ype-specific OPA GMT ratios for each of the 15 
seroty pes in V114 and strain -specific HAI GMT ratios for ea ch of the 4 strains in QI V, 
respectivel y.Estimation of the ratios , 95% CI, and the hy pothesis test (i.e., 1 -sided p -value) 
will be calculated using a constrained longitudinal data analysis (cLDA)method proposed by  
Liang and Zeger [Liang, K -Y and Zeger, S. L. 2000] utilizing data from both vaccination 
groups . In this model, the response vector consists of the log -transformed baseline and 30 
days post vaccination antibody  titers . The repeated -measures model will include terms for 
vaccination group, time, the interaction of time -by-vaccination group (with a restriction of 
the same baseline mean across groups), age stratum (i.e., 50 to 64 y ears, 65 to 74 y ears, and 
≥75 y ears) at baseline , history of prior PNEUMOVAX™23 stratum (i.e., Yesand No), age 
stratum -by-time interaction , and history of prior PNEUMOVAX™23 stratum -by-time
interaction . This model will allow for different baseline means for each stratum, but restrict 
the baseline mean within both the age stratum levels and the history stratum levels to be the 
same for both vaccination groups . An unstructured covariance matrix will be used to model 
the correlation among repeated measurements . The Kenward -Roger a djustment will be used 
with restric ted (or residual) maximum likelihood to make proper statistical inference . This 
model allows the inclusion of participants who are missing either the baseline or postbaseline 
measurements, thereb y increasing efficiency . 
  04Y38Y 
  05FQSH
PRODUCT: V114 65
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
A similar statistical approach wil l be used to evaluate the serot ype-specific IgG GMCs at 30 
days postvaccination with V114 for participants administered V114 concomitantly  with QIV
and participants administered V114 nonconcomitantly  with QIV. 
Descriptive statistics with point estimates and within -group 95% C Is will be provided for all 
other immunogenicit y endpoints. For the continu ous endpoints, the point estimates will be 
calculated b y exponentiating the estimates of the mean of the natural log values and the 
within -group CIs will be de rived b y exponentiating the CIs of the mean of the natural log 
values based on the t -distribution. For the dichotomous endpoints, the within -group CIs will 
be calculated based on the exact method proposed by  Clopper and Pearson [Clopper, C. J. 
and Pearson, E. S. 1934] .
Reverse Cumulative D istribution Curvesfor both OPA titers and IgG concentrations at 30 
days postvaccination with V114 will be graphically display ed by serotype. Reverse 
Cumulative Distribution Curvesfor HAI titers at 30 day s postvaccination with QIVwill be 
graphica lly display ed by strain .
A detailed analy sis strategy  for key immunogenicity  endpoints is listed in Table 4.
Table 4 Analy sis Strategy  for Immunogenicit y Variables
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical Method‡Analysis 
PopulationMissing 
Data 
Approach
Prim ary Endpoint s
OPA GMTs at30 days postvaccination with 
V114PcLDA§
(estimate, 95% CI)PP
Model -based
S FAS
HAI GMTs at30 days postvaccination with 
QIVPcLDA§
(estimate, 95% CI)PP
Model -based
S FAS
Secondary Endpoints
IgG GMCs at 30 days postvaccination with
V114PcLDA§
(estimate, 95% CI)PP Model -based
OPA GMTs and IgG GMCs atbaseline
(prevaccination with V114 )and30 days 
postvaccination with V114PDescriptive 
Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
GMFR sand %sof participants with a ≥4-
fold rise from baseline (prevaccination with
V114 ) to 30 days postvaccin ation with
V114 for both OPA and IgG responsesPDescriptive 
Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
HAI GMTs at baseline ( prevaccination 
with QIV)and 30 days postvaccination
with QIVPDescriptive 
Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
HAI GMFR sfrom baseline (prevaccination 
with QIV) to 30 days postvaccination with
QIVPDescriptive 
Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed 
  04Y38Y 
  05FQSH
PRODUCT: V114 66
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical Method‡Analysis 
PopulationMissing 
Data 
Approach
%sof participants with HAI titer ≥1:40 at 
30 days postvaccination with QIVPDescriptive 
Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
%sof participants that seroco nvert at 30 
days postvaccination with QIV for HAI 
responsesPDescriptive 
Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
†P =Primary approach; S =Supportive approach.
‡Statistical models are described in further detail below:
§Constrained longitudinal data analysis (cLDA) model with terms for vaccination group, time, the interaction 
of time -by-vaccination , age stratum at baseline, history of prior PNEUMOVAX™23 stratum , age stratum -
by-time interaction, and history of prior PNEUMOVAX™23 stratum -by-timeinteraction .
CI= confidence interval ; FAS = Full Analysis Set; GMC = Geom etric Mean Concentration; 
GMFR =geometric mean fold rise; GM =Geom etric Mean Titer; IgG = Immunoglobulin G; OPA=
opsonophagocytic activity ; PP =Per-Protocol ; HAI= hemagglutination inhibition ; QIV =quadrivalent 
influenza vaccine (seasonal inactivated).
9.6.2 Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
AEs and postvaccination temperature measurements.
The anal ysis of safet y results following an y vaccination will follow a tiered approach 
(Table 5). The tiers differ with respect to the anal yses that will be performed. AEs (specific 
terms as well as s ystem organ class terms) are either pre -specified as “Ti er 1” endpoints, or 
will be classified as belonging to "Tier 2" or "Tier 3" based on the number of events 
observed.
Tier 1 Events
Safety  parameters or AEs of special interest that are identified a priori constitute “Tier 1” 
safet y endpoints that will be s ubject to inferential testing for statistical significance with p -
values and 95% CIs to be provided for between -group differences in the proportion of 
participants with events; these anal yses will be performed using the unstratified Miettinen 
and Nurminen (M&N) method [Miettinen, O. and Nurminen, M. 1985] , an unconditional, 
asymptotic method. For this protocol, solicited injection -site AEs (redness/ery thema, 
swelling, tenderness/pain) from Day  1 through Day  5 following an y vaccination and solicited 
systemic AEs (muscle pain/my algia, joint pain/arthralgia, headache, and tiredness/fatigue) 
from Day  1 through Day  14 following an y vaccination are considered Tier 1 events. 
  04Y38Y 
  05FQSH
PRODUCT: V114 67
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences 
in the proportion of participants with events (also via the unstratified M&N method 
[Miettinen, O. and Nurminen, M. 1985] ).
Membership in Tier 2 requires that at least 4 participants in any  vaccination group exhibit the 
event. The threshold of at least 4 events was chosen because the 95% CIfor the between -
group difference in percent incidence will always include zero when vaccination groups of 
equal size each have less than 4 events and thus would add little to the interpretation of 
potentially  meaningful differences. Because man y 95% CIs for Tier 2 events may  be 
provided without adjustment for multiplicity , the CIs should be regarded as a helpful 
descriptive measure to be used in review, not a formal method for assessing the statistical 
significance of the between -group differences in adverse events.
In addition to individual events that occur in 4 or more participants in an y vaccination group, 
thebroad AE categories consisting of the proportion of participants with any AE, a vaccine -
related AE, a SAE, an AE which is both vaccine -related and serious, discontinuation due to 
an AE, and the proportion of participants who died will be considered Tier 2 endpoints . The 
proportion of participants with maximum temperature measurements meeting the Brighton 
Collaboration cut points will also be considered Tier 2 endpoints.
Tier 3 Events
Safety  endpoints that are not Tier 1 or 2 events are considered Tier 3 e vents. Only  point 
estimates by  vaccination group are provided for Tier 3 safety  parameters.
Table 5 Analy sis Strategy for Safety  Parameters Following An y Vaccination
Safety Tier Safety Endpoint p-Value95% CI for 
Betw een-Group 
Com parisonDescriptive 
Statistics
Tier 1 Injection -site redness/ erythema (Days 1 to 5) X X X
Injection -site swelling (Days 1 to 5) X X X
Injection -site tenderness/pain (Days 1 to 5) X X X
Muscle pain/myalgia (Days 1 to 14) X X X
Joint pain /arthralgia (Days 1 to 14) X X X
Headache (Days 1 to 14) X X X
Tiredness/fatigue (Days 1 to 14) X X X 
  04Y38Y 
  05FQSH
PRODUCT: V114 68
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Safety Tier Safety Endpoint p-Value95% CI for 
Betw een-Group 
Com parisonDescriptive 
Statistics
Tier 2 Any AE†X X
Any vaccine -related AE†X X
Any SAE†X X
Any vaccine -related SAE†X X
Discontinuation due to AE†X X
Death†X X
Maximum temperature measurements meeting the 
Brighton Collaboration cut points (Days 1 to 5) X X
Specific AEs bySOC and PT‡(incidence ≥4 of 
participants in 1of the vaccination groups)X X
Tier 3 Specific AEs bySOC and PT‡(incidence < 4 of 
participants in all of the vaccination groups)X
†These endpoints are broad adverse event categories. For example, descriptive statistics for the safety 
endpoint of “Any AE” will provide the number and percentage of participants with at least 1AE. 
‡Includes only those endpoints not pre -specified as Tier 1 or not already pre -specified as Tier 2 endpoints.
AE=adverse event; PT=preferred term; SAE =serious adverse event; SOC = system organ class ; X=results 
will be provided.
In addition to the anal yses following an y vaccination, point estimates by  vaccination group 
will be provided for injection -site AEs following V114 and following QIV separately .That 
is, the proportion of participants with injection -site AEs following admin istration of V114 
will include AEs reported from Day  1 through Day  5 following V114 administration in the 
limb corresponding to the location of V114 administration. Similarly , the proportion of 
participants with injection -site AEs following administration of QI V will include AEs 
reported from Day  1 through Day  5 following QIV administration in the limb corresponding 
to the location of QIV administration.
Additionally , the s ystemic AEs in the 14 day s following each vaccination time point for each 
vaccination group will be summarized. That is, descriptive summaries of systemic AEs will 
include AEs reported from Day  1 through Day  14following administration of
1.V114 and QIV in the concomitant group at Visit 1 (Day  1)
2.QIV with placebo in the nonconcomitant group at Visit 1 (Day  1)
3.Placebo alone in the concomitant group at Visit 2 (Day  30)
4.V114 alone in the nonconcomitant group at Visit 2 (Day  30)
Safety  anal yses will be based on the observed data (ie , with no imputation of missing data) .  
  04Y38Y 
  05FQSH
PRODUCT: V114 69
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
9.6.3 Demographic and Baseline Characteristics
The comparability  of the vaccination groups for each relevant demographic and baseline 
characteristic will be assessed b y the use of summary  tables . No statistical hy pothesis tests 
will be performed on these characteristics. The number and percentage of participants 
screened and randomized a nd the primary  reasons for screening failure and discontinuation 
will be display ed. Demographic variables (eg, age , race, and gender ), baseline characteristics, 
prior and concomitant vaccinations and therapies will be summarized by  vaccination group 
either b y descriptive statistics or categorical tables .
9.7 Interim Analyses
A periodic review of safety  and tolerability  data across the adult V114 Phase 3 program will 
be conducted b y an independent, unblinded, external DMC . A description of the structure, 
function, and guidelines for decision -making by  the DMC, along with the timing and content 
of the safet y reviews will be outlined in the DMC charter. Information regarding the 
composition of the DMC is provided in Appendix 1. There are no plans to conduct an interim 
analysis of unblinded immunogenicit y data in this study. However, unblinded 
immunogenicit y data will be made available to the DMC upon request to enable a benefit -
risk assessment.
Study  enrollment is likely  to be ongoing at the time of any  interim analy ses. Blinding to 
intervention assignment will be maintained at all investigational sites. The results of interim 
analyses will not be shared with the investigators prior to the completion of the study. 
Participant -level unblinding will be restricted to an external unblinded statistician performing 
the interim anal ysis.The DMC will serve as the primary reviewer of the results of the safet y 
interim analy ses and will make recommendations for discontinuatio n of the study  or protocol 
modifications to an executive committee of the Sponsor (see Appendix 1 for details on the 
Committees Structure for this study ). If the DMC recommends modifications to the design of 
the protocol or discontinuation of the study, th is executive committee (and potentially  other 
limited Sponsor personnel) may be unblinded to results at the intervention level in order to 
act on these recommendations. The extent to which individuals are unblinded with respect to 
results of interim anal yses will be documented b y theexternal unblinded statistician . 
Additional logistical details will be provided in the DMC Charter. 
Intervention -level results from the safety  interim analy sis will be provided by  the external 
unblinded statistician to the DMC . Prior to final study  unblinding, the external unblinded 
statistician will not be involved in any discussions regarding modifications to the protocol, 
statistical methods, identification of protocol deviations, or data validation efforts after the 
interim analy ses.
9.8 Multiplicity
The overall success of the study  requires demonstrat ing success on all 15 pneumococcal 
serotypes and all 4 influenza strains included in the primary  immunogenicity  hypothes es.
This approach controls the 1 -sided type-I error rate at 0.025 , and no multiplicity  adjustment 
will be required. 
  04Y38Y 
  05FQSH
PRODUCT: V114 70
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
This study  will randomize approximately  600participants into the concomitant group and 
600participants into the nonconcomitant group and has a pproximately  87% power for 
demonstrating noninf eriority  of the serot ype-specific OPA GMT ratio sfor the 15
pneumococcal serot ypes included in V114 and >99.9% power for demonstrating 
noninfer iority  of the strain -specific HAI GMT ratiosforthe4 influenza strains in QI V at an 
overall 1-sided 2.5% alpha -level. Because the 2hypotheses are assumed to be independent 
and the success of the study  requires that the stati stical criteria be met for both hypotheses, 
the overall power for the primary  immunogenicity  hypotheses is estimated to be 
approximately  87% (=0.87× >0.999) .
The sample size and power calculations are based on the following assumptions:
90% evaluability  rate (approximately  540 evaluable participants per treatment group) 
for both primary  endpoints (OPA GMT ratios and HAI GMT ratios) .
The underl ying OPA GMT ratio is 0.8 0(concomitant/nonconcomitant) for the 15 
pneumococcal serot ypes. Theassumption for this ratio is 
based on results of studies 
evaluating the administration of Prevnar 13™ with concomitant influenza vaccine s.
The variabilit iesfor OPA titers in both concomitant group and nonconcomitant group 
are the same as that observed in V114 -006. The standard d eviation sof the natural log 
titers for the 15 pneumococcal ser otypes in V114 range from 1.3 3to 2.24.The lowest 
estimated GMT ratios (concomitant group /nonconcomitant group ) that would still 
meet the noninfer iority margin range from 0.59 to 0.65. 
The HAI antibody  responses are the same as those observed in a prior Merck study .
9.9.2 Sample Size and Power for Safety Analyses
The probability  of observing at least 1SAE in this study  depends on the number of 
participants vaccinated and the underl ying incidence of participants with a SAE in the study  
population. Calculations below assume that 100% of the randomized participants will be 
evaluable for safet y analyses. There is an 80% chance of observing at least 1SAE among 
600participants in the concomitant group if the underly ing inci dence of a SAE is 0.27% (1 
of every  373participants receiving the vaccine). There is a 50% chance of observing at least 
1SAE among 600participants in the concomitant group if the underl ying incidence of a SAE
is 0.12% (1 of every  866participants receiv ing the vaccine). If no SAE s are observed among 
600participants in the concomitant group, this study  will provide 97.5% confidence that the 
underly ing percentage of participants with a SAE is <0.61% (1in every  163participants) in 
the concomitant group. 
  04Y38Y 
  05FQSH
PRODUCT: V114 71
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Table 6summarizes the percentage point differences between the 2 vaccination groups that 
could be detected with 80% probability  for a variety  of hypothetical underly ing incidences of 
an AE. These calculations assume 600 participants in each group and a re based on a 2 -sided 
5% alpha level. The calculations are based on an asy mptotic method proposed by  Farrington 
and Manning (1990) [Farrington, C. P. 1990] ; no multiplicity  adjustments were made.
Table 6 Differences in Incidence of AERates between the 2Vaccination Group sThat Can 
be Detected With an ~80% Probability  (Assuming 2-sided 5% alpha level with 6 00 
Participants in each Group)
Incidence of Adverse Event Risk Difference
Nonconcomitant Group (%) Concomitant Group (%) Percentage Points
0.1 1.6 1.5
2.0 5.0 3.0
5.0 9.1 4.1
10.0 15.4 5.4
15.0 21.2 6.2
20.0 26.8 6.8
30.0 37.6 7.6
Incidences presented here are hypothetical and do not represent actual adverse experiences in either group.
Based on an asymptotic method (Farri ngton and Manning [1990 ])
9.10 Subgroup Analyses
Subgroup anal yses will be performed for the primary  immunogenicity  endpoint sand selected 
safet y endpoints (summary of AEs and summary of solicited AEs) . Examples of possible 
subgroup classification variables include age (50 to 64 y ears, 65 to 74 y ears, and ≥75 y ears)
and history  of PNEUMOVAX ™23 vaccination (Yes and No). Further details of subgroup 
analyses will be documented in the Supplemental Statistica lAnaly sis Plan.
9.11 Compliance (Medication Adherence)
Given that participants will receive just a single dose of V114 and a single dose of QIV, 
compliance will not be calculated. However, the number and proportion of randomized 
participants receiving each vacc ination will be summarized (Section 9.12).
9.12 Extent of Exposure
The extent of exposure will be summarized by  the number and proportion of randomized 
participants administered V114 and the number and proportion of randomized participants 
administered QIV. 
  04Y38Y 
  05FQSH
PRODUCT: V114 72
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10 SUP PORTING DOCUMENTATIO N AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzin g and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in c ompliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical an d scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is no t intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous pe rformance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites ar e monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard oper ating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues  
  04Y38Y 
  05FQSH
PRODUCT: V114 73
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results o f its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD’s policy on authorship is consistent with the re commendations published by the International Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contri bution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publi cations.
III.Participant Protection
A. Ethics Committee Review (Institutiona Review Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by an IRB/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except 
changes required urgently to prot ect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the par ticipant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials i s that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All p articipation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or representative), ethics committee, and/or regulator y authorities will have 
access to confidential medical records t hat might identify the participant by name.
D. Genomic Research
Genomic r esearch will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics c ommittee.
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. Howeve r, MSD may compensate referring physicians for time spent 
on chart review to identify potentially eligible participants. 
  04Y38Y 
  05FQSH
PRODUCT: V114 74
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meeti ngs, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these et hical a nd scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determin e, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the Un ited States for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by the Sponsor. An y participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance audito rs or other authori zed personnel appointed by  the S ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities. 
  04Y38Y 
  05FQSH
PRODUCT: V114 75
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.1.3.1 Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y wit h such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as provided in the Publications section of this pro tocol.
10.1.3.2 Confidentiality of Participant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF report form data. By  signing the consent form, the participant agrees 
to this process. If stud y documents will be photocopied during the process of verifying 
worksheet/ CRF information, the participant will be identified b y unique code only; full 
names/initi als will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y req uesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
10.1.4 Committees Structure
10.1.4.1 Scientific Advisory Committee
This study  was develo ped in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent peer -reviewed 
scientifi c publications.
10.1.4.2 Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprise d  of members of Sponsor Senior 
Management. The EOC will receive and decide upon any  recommendations made by  the
DMC regarding the study. 
  04Y38Y 
  05FQSH
PRODUCT: V114 76
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.1.4.3 External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study . The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be in volved with the study  in an y other 
way (eg, they  cannot be study  investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both partic ipant 
safet y and the continued ethical integrity of the study. Also, the DMC will review interim 
study  results, consider the overall risk and benefit to study  participants (Section 9.7) and 
recommend to the EOC whether the stud y should continue in accordance with the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the s tudy governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by all the DMC members.
10.1.5 Publication Policy
The results of this study  may be published or presented at scientific meetings. The Sponsor 
will comply  with the requirements for publication of study  results. I n accordance with 
standard editorial and ethical practice, the Sponsor will generall y support publication of 
multicenter st udies only  in their entiret y and not as individual site data. I n this case, a 
coordinating investigator will be designated b y mutual agreement.
If publication activity is not directed b y the Sponsor, the investigator agrees to submit all 
manuscripts or abs tracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary  information and to provide comments.  
Authorship will be determined by  mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements.
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
ofthe study  is solel y responsible for determining whether the stud yand its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropria te studies for their 
disease conditions and pursue participation b y calling a central contact number for further 
information on appropriate study  locations and study  site contact information. 
  04Y38Y 
  05FQSH
PRODUCT: V114 77
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this study or its results to those 
registries. 
10.1.7 Compliance with Law, Audit, an d Debarmen t
By signing this protocol, the investigator agrees to conduct the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use G CP: Consolidated Guideline and other generally  
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical investigations sponsored b y MSD, is provided i n this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conduct ing or working on clinical studies by  any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsor’s studies. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the s tudy is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted t o the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct by  
physicall y or electronically signing the CRF.
Detailed information regarding D ata Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
  04Y38Y 
  05FQSH
PRODUCT: V114 78
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study sit e upon request for inspection, 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and th at the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  mus t 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may  be 
transferred to another location or part y without written notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to req uest previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
10.1.10 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor will 
promptly  notify  that study  site’s IRB/IEC. 
  04Y38Y 
  05FQSH
PRODUCT: V114 79
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.2 Appendix 2: Clinical La boratory Tests
The tests detailed in Table 7will be performed according to local requirements. 
Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 5 of the protocol.
Additional tests may  be performed at an y time during the stud y as determined 
necessary  by the investigator or required b y local regulations.
Table 7 Protocol -Require d Safet yLaboratory Assessments
Laboratory  
AssessmentsParameters
Other 
Screening 
TestsSerum or urine β-hCG pregnancy  test (as needed for WOCBP)
β-hCG = β human chorionic gonadotropin; WOCBP = woman/women of 
childbearing potential 
  04Y38Y 
  05FQSH
PRODUCT: V114 80
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be an y unfavorable and unin tended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) inc ludes an y pharmaceutical product, biological product, vaccine, device, 
diagnostic agent, or protocol specified procedure whether investigational (including 
placebo or active comparator product) or marketed, manufactured b y, licensed by, 
provided b y, or dis tributed by  the Sponsor for human use in this study .
Events meeting the AE definition
•Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, or are considered clinicall y significant in the 
medical and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/o r intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
Any new cancer or progression of existing cancer. 
  04Y38Y 
  05FQSH
PRODUCT: V114 81
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
•Surgery  planned prior to informed consent to treat a pre -existing condition that has not 
worsened .
•Refe r to Section 8.4.7 for protocol -specific exceptions.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious ”refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
•Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a precautionary  measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre -existing c ondition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
d.Results in persistent or significant disability/inca pacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions. 
  04Y38Y 
  05FQSH
PRODUCT: V114 82
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the produ ct regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospitalization but may  
jeopardize the participant or may require medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory , and diagnostics reports) related to 
the even t.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination. 
  04Y38Y 
  05FQSH
PRODUCT: V114 83
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
•It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may  be instances when copies of medical records for certain cases are requested b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copies of the medical record s before submission to the 
Sponsor.
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity /Toxicity
•An event is defined as “serious ”when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort 
and not interfering with every day activities (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies definitel y acting like something is wrong).
-Severe: An eve nt that prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe (for 
pediatric studies, extr emely  distressed or unable to do usual activities).
•Injection -site redness /erythema or swelling from the day of vaccination through Day  5 
postvaccination will be evaluated b y maximum size.
•The investigator will make an assessment of toxicity for each AE and SAE (and other 
reportable event) reported during the stud y.  A toxicity  grade will be assigned to 
injection -site AEs, specific sy stemic AEs, other s ystemic AEs, and vital sign 
(temperature) AEs as shown in the following tables. The toxicity  grading sca les used in 
this study  are adapted from the “FDA Guidance for Industry : Toxicity  Grading Scale for 
Health y Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, 
September 2007.” 
  04Y38Y 
  05FQSH
PRODUCT: V114 84
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Injection -Site AE Toxicity Grading Scale
Injection S ite Reaction 
to Study 
Vaccine/PlaceboaGrade 1 Grade 2 Grade 3 Grade 4
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityERvisit or 
hospitalization
Erythema/Redness Size measured as
BSize measured as
C or DSize measured as
E→Necrosis or 
exfoliative dermatitis 
or results in ER visit 
or hospitalization
Induration/Swelling Size measured as 
BSize measured as
C or DSize measured as
E→Necrosis or ER visit 
or hospitalization
Other Does not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interf eres with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospitalization
Any injection -site reaction that begins ≥ 6 days after receipt of study vaccine/placebo
Pain/tenderness
Erythema/Redness
Induration/Swelling
OtherDoes not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospitalization
Abbreviations: AE = adverse event; ER = emergency r oom; eVRC = electronic Vaccine Report Card; SAE = serious 
adverse event
a Based upon information provided by the patient on the eVRC and verbally during VRC review. Erythema/Redness and 
Induration /Swelling are specific injection -site AEs with size designations of letters A through E →, based upon a graphic in 
the eVRC.  Size A is not assigned a toxicity grade; however, injection -site AEs that measure size A should be reported as 
adverse experiences.  If the participant has an ER visit or is hospitali zed for any injection -site AE, that AE is to be assigned 
a toxicity grade of 4, regardless of the size measured.
Specific Systemic AE Toxicity Grading Scale
System ic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference with 
activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use of 
narcotic pain reliever 
or prevents daily 
activityER visit or 
hospitalization
Fatigue No interference with 
activitySome interference with 
activitySignificant; prevents 
daily activityER visit or 
hospitalization
Myalgia No interference with 
activitySome interference with 
activitySignificant; prevents 
daily activityER visit or 
hospitalization
Abbreviations: ER = emergency room 
  04Y38Y 
  05FQSH
PRODUCT: V114 85
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Other Systemic AE Toxicity Grading Scale
System ic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined according 
to applicable 
regulations)No interference with 
activitySome interference with 
activity not requiring 
medical interventionPrevents daily activity 
and required medical 
interventionER visit or 
hospitalization
Abbreviations: ER = emergency room; eVRC = electronic Vaccine Report Card; SAE = serious adverse event
aBased upon information provided by the patient on the eVRC and verbally during the eVRC review during the primary 
safety follow -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based upon the 
initial report and/or f ollow -up of the event.
bAEs resulting in death will be assessed as Grade 4
Vital Sign (Temperature) Toxicity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (°C) b
(°F) b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.0
aParticipant should be at rest for all vital sign requirements
b Oral temperature; no recent hot or cold beverages or smoking
Assessment of c ausality
•Didthe Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initia lled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (diary , 
etc.), seroconversion or identification of vaccine virus in bodily  specimen? 
  04Y38Y 
  05FQSH
PRODUCT: V114 86
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? I s the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonabl y explained by  another etiology  such as 
underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors ?
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulte d in death or permanent 
disability , or (2) the study  is a single -dose vaccine study ); or (3) Sponsor ’s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR ’S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY THE SPONSOR CLINI CAL  DIRECTOR, AND IF REQUI RED, THE 
IRB/IEC .
-Consistency with study intervention profi le:Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor ’s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs /worksheets by an 
investigator who is a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship) .
-Yes, there is a reasonable possibility  of Sponsor ’s product relationship:
-There is evidence of exposure to the Sponsor ’s product. The temporal sequence of the 
AE onset relative to the administration of the Sponsor ’s product is reasonable. The 
AE is more likely  explained by  the Sponsor ’s product than by  another cause.
-No, there is not a reasonable possibility  of Sponsor ’s product relationship: 
  04Y38Y 
  05FQSH
PRODUCT: V114 87
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
-Participant did not receive the Sponsor ’s product OR temporal sequence of the AE 
onset relative to administration of the Sponsor ’s product is not reasonable OR the AE 
is more likely  explained by  another cause than the Sponsor’s product. (Also entered 
for a participant with overdose without an associated AE.)
•For each AE/SAE, the investigator must document in the medic al notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change his/her opinion of causality  in light of follow -up 
information and send an S AE follow -up report with the updated causality  assessment.
•The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathologica l examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE , SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•The primary  mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) too l.
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent). 
  04Y38Y 
  05FQSH
PRODUCT: V114 88
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
•If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Reference Section 8.4.1 for reporting ti me requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•Ifa site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by telephone (see next sectio n).
•Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
•Initial noti fication via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent). 
  04Y38Y 
  05FQSH
PRODUCT: V114 89
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Not applicable 
  04Y38Y 
  05FQSH
PRODUCT: V114 90
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
10.5.1 Definitions
Wome n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the fol lowing:
- Documented h ysterectomy
-Documented bilateral salpingectomy
-Documented bilateral oophorectom y
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history  interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause .
•A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not usin g hormonal contraception or 
hormone replacement therap y (HRT). However, in the absence of 12 months of 
amenorrhea, confirmation with 2 FSH measurements in the postmenopausal range is 
required.
-Females on HRT and whose menopausal status is in doubt will be required to use 1 of 
the nonhormonal highl y effective contraception methods if they wish to continue their 
HRT during the stud y. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status before stud y enrollment.
10.5.2 Contraception Requ irements
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to use 
1of the contraception methods described in Table 8consistently  and correctly  during the 
protocol -defined time frame in Section 5.1. 
  04Y38Y 
  05FQSH
PRODUCT: V114 91
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Table 8 Contraceptive Methods
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
●Male or female condom with or without spermicide
●Cervical cap, diaphragm or sponge with spermicide
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when used consistently and correctly.
●Com bined (estrogen -and progestogen -containing) hormonal contraceptionb
○Oral
○Intravaginal
○Transdermal
○Injectable
●Progestogen only hormonal contraceptionb
○Oral
○Injectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
●Progestogen -only contraceptive implantb
●Intrauterine hormone -releasing system (IUS)b
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the 
sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an 
additional highly effective method of contraception should be used.
●Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive methods for participants 
of clinical studies.
aTypical use failure rates are higher than perfect -use failure rates (ie, when used consistently and 
correctly).
bIf locally required , in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
hormonal contraceptives are limited to those which inhibit ovulation. 
  04Y38Y 
  05FQSH
PRODUCT: V114 92
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.5.3 Pregnancy Testing
WOCBP should only  be included after a negative highl y sensitive urine or serum pregnancy  
test.
Pregnancy  testing will be performed whenever an expected menstrual cy cle is missed or 
when pregnancy  is otherwise suspected. 
  04Y38Y 
  05FQSH
PRODUCT: V114 93
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
Biomarker: A biologi cal molecule found in blood, other bod y fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition . 
Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
DNA: Deox yribonu cleic acid.
RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 8will be 
used in various experiments to understand:
The biology  of how drugs/vaccines work
Biomarkers re sponsible for how a drug/vaccine enters and is removed b y the body
Other pathway s drugs/vaccines may  interact with
The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health th rough development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by the Sponsor or those working for or 
with the Sponsor. 
  04Y38Y 
  05FQSH
PRODUCT: V114 94
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
3.Summary of Procedures for Future Biomedical Research .
Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in the 
future biomedical research substudy
Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enroll ment from all participants at a stud y visit by  the 
investigator or his or her d esignate. Informed consent for future biomedical r esearch 
should be presented to the participants on the visit designated in the SoA. If delayed, 
present consent at next possibl e Participant Visit. Consent forms signed b y the 
participant will be kept at the clinical study site under secure storage for regulatory 
reasons.
A template of each stud y site’s approved informed consent will be stored in the 
Sponsor’s clinical document re pository .
eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroy ed.
Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obta ined at a time when the participant is 
having blood drawn for other study  purposes.
4.Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history  and treatment outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below. 
  04Y38Y 
  05FQSH
PRODUCT: V114 95
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube.
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by the Sponsor, or an additional third party (eg, a universit y investigator) designated b y 
the Sponsor. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this subs tudy. Future biomedical r esearch 
specimens remaining with the third part y after specific anal ysis is performed will be 
reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical research and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contacting the principal investigator for the main study. If medical 
records for the main study are still available, the in vestigator will contact the Sponsor 
using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only . If specimens were collected fro m study participants 
specificall y for future biomedical r esearch, these specimens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the respon sibility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b ythe Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situati on, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to 20 y ears from the end of the main study . Spec imens may  be stored for 
longer if a regulatory  or governmental authorit y has active questions that are being  
  04Y38Y 
  05FQSH
PRODUCT: V114 96
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the study  site will be shipped to a central laboratory  and then shipped to 
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
study , the stud y site will ship directly to the Sponsor -designated biorepository . The 
specimens will be stored under strict supervision in a limited access facility which 
operates to assure the integrity of the specimens. Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database.
8.Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regard ing misinterpretation.
If important research findings are discovered, the Sponsor may
 publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and particip ants. Participants will not be 
identified by  name in any published reports about this study  or in any  other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the Future Biomedical Research inf ormed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely situation, there is risk that the 
information, like all medical information, may  be misused. 
  04Y38Y 
  05FQSH
PRODUCT: V114 97
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
12.Questions
Any questions related to the future biomedical research should be e mailed directly  to 
clinical.specimen.management@merck.com.
13.References
National Canc er Institute [I nternet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618
International Conference on Harmonization [Internet] : E15 : Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Dat a and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions -
for-genomic -biomarkers -pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
Industry  Pharmacogenomics Working Group [Internet]: Pharma cogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i -pwg.org/ 
  04Y38Y 
  05FQSH
PRODUCT: V114 98
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.7 Appendix 7: Country -specific Requirements
Not applicable 
  04Y38Y 
  05FQSH
PRODUCT: V114 99
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
AE adverse e vent
APaT All Participants as Treated
β-hCG beta-human chorionic gonadotropin
CAPiTA Community -Acquired Pneumonia Immunization Trial in Adults
CFR Code of Federal Regulations
CI confidence interval
cLDA constrained longitudinal data a nalysis
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CSR Clinical Study R eport
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
ECL electrochemiluminescence
eCRF electronic case report form
EDC electronic data collection
EMA European Medicines Agency
EOC Executive Oversight Committee
eVRC Electronic Vaccination Report Card
FAS Full Analysis Set
FDAAA Food and Drug Administration Amendments Act
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GMC Geometric Mean C oncentration
GMFR Geometric Mean Fold R ise
GMT Geometric M ean Titer
HIV Human Immunodeficiency Virus
HRT hormone replacement therapy
IB Investigator’s Brochure
ICF Informed Consent F orm
ICH International Council for Harmonisation Good Clinical Practice
IEC Independent Ethics Committee
IgG immunoglobulin G
IMP investigational medicinal product
IPD invasive pneumococcal disease
IRB Institutional Review Board
IRT interactive response technology
IUD intrauterine device
IUS intrauterine hormone -releasing s ystem
MOPA Multiplexed Opsonophagocytic Assay
MSD Merck Sharp & Dohme Corp.
NIMP non-investigational medicinal product
OPA opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PnECL pneumococcal electrochemiluminescence
PP Per-Protocol 
  04Y38Y 
  05FQSH
PRODUCT: V114 100
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
Abbreviation Expanded Term
PT preferred term
RNA ribonucleic acid
SAC Scientific Advisory Committee
SAE serious adverse e vent
SLAB supplemental laboratory test
SoA schedule of activities
SOC system organ class
SUSAR suspected unexpected serious adverse reaction
US United States
WOCBP woman/women of childbearing potential 
  04Y38Y 
  05FQSH
PRODUCT: V114 101
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
11 REFERENCES
[Anttila, M., et al 1999] Anttila M, Voutilainen M, Jäntti V, Eskola J, Käyht y 
H. Contribution of serotype -specific IgG 
concentration, IgG subclasses and relative antibody  
avidity  to opsonophagocy tic activity  against 
Streptococcus pneumoniae. Clin Exp I mmunol 
1999;118(3):402 -7.03QY70
[Bonten, M. J., et al 
2015]Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, 
Patterson S, Gault S, et al. Poly saccharide conjugate 
vaccine against pneumococcal pneumonia in adults. N 
Engl J Med. 2015 Mar 19;372(12):1114 -25.04NFHD
[Burton, Robert L . and 
Nahm, Moon H. 2006]Burton RL, Nahm MH. Development and validation 
of a fourfold multiplexed opsonization assay  
(MOPA4) for pneumococcal antibodies. Clin Vaccine 
Immunol 2006;13(9):1004 -9.03QT2R
[Centers for Disease 
Control and Prevention 
(CDC) 2010]Centers for Disease Control and Prevention (CDC). 
Estimates of deaths associated with seasonal influenza 
---United States, 1976 -2007. MMWR Morb Mortal 
Wkly  Rep. 2010 Aug 27 ;59(33):1057 -62.04NJRX
[Centers for Disease 
Control and Prevention 
2008]Centers for Disease Control and Prevention (CDC). 
Invasive pneumococcal disease in children 5 years 
after conjugate vaccine introduction -eight states,1998 -
2005. MMWR Morb Mortal Wkl y Rep. 2008 Feb 
15;57(6):144 -8.04KW8S
[Centers for Disease 
Control and Prevention 
2010]Centers for Disease Control and Prevention. 
Prevention of Pneumococcal Disease Among Infants 
and Children -Use of 13 -Valent Pneumococcal 
Conjugate Vaccine and 23 -Valent Pneumococcal 
Polysaccharide Vaccine; Recommendations of the 
Advisory  Committee on Immunization Practices 
(ACI P). MMWR 2010;59(RR -11):1 -19.03RSB6
[Clopper, C. J. and 
Pearson, E. S. 1934]Clopper CJ, Pearson ES. The use of confidence or 
fiducial limits illustrated in the case of the binomial. 
Biometrika 1934;26(4):404 -13.03Q0L W
[Dominguez, A., et al 
2013]Dominguez A, Castilla J, Godoy  P, Delgado -
Rodriguez M, Saez M, Soldevila N, et al. 
Effectiveness of vaccination with 23 -valent 
pneumococcal poly saccharide vaccine in preventing 
hospitalization with laboratory confirmed influenza 
during the 2009 -2010 and 2010 -2011 seasons. Hum 
Vaccin Immunother. 2013 Apr;9(4):865 -73.04WX4B 
  04Y38Y 
  05FQSH
PRODUCT: V114 102
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
[Drijkoningen, J. J 
2014]Drijkoningen JJ, Rohde GG. Pneumococcal infection 
inadults: burden of disease. Clin Microbiol I nfect. 
2014 May ;20 Suppl 5:45 -51.04NFHN
[ECDC 2017] European Centre for Disease Prevention and Control. 
Seasonal influenza vaccination in Europe: vaccination 
recommendations and coverage rates in the EU 
Member States for eight influenza seasons: 2007 –
2008 to 2014 –2015 [I nternet]. Stockholm: ECDC; 
2017 Jul. 40 p. Available from: 
https://ecdc.europa.eu/sites/portal/files/documents/infl
uenza- vaccination -2007%E2%80%932008 -to-
2014%E2%80%932015.pdf.04W7G2
[European Centre for 
Disease Prevention and 
Control 2016]European Centre for Disease Prevention and Control. 
Annual Epidemiological Report 2016 –Invasive 
pneumococcal disease. [Internet]. Stockholm: ECDC; 
2016. Available from: 
http://ecdc.europa.eu/en/healthtopics /pneumococcal_i
nfection/Pages/Annual -epidemiological -report -
2016.aspx.04LP3M
[European Medicines 
Agency  2016]European Medicines Agency . Guideline on influenza 
vaccines: non- clinical and clinical module. L ondon: 
European Medicines Agency . 2016. 31 p. (EM A 
publication; no. EMA/CHMP/VWP/457259/2014).04W9SY
[Farrell, D. J, et al 
2007]Farrell DJ, Klugman KP, Pichichero M. Increased 
antimicrobial resistance among nonvaccine serot ypes 
of Streptococcus pneumoniae in the pediatric 
population after the introduction of 7 -valent 
pneumococcal vaccine in the United States. Pediatr 
Infect Dis J. 2007 Feb;26(2):123 -8.04KWD9
[Farrington, C. P. 1990] Farrington CP, Manning G. Test Statistics and Sample 
Size Formulae for Comparative Binomial Trials with 
Null Hy pothesis of Non -Zero Risk Difference or Non -
Unity  Relative Risk. Stat Med Vol. 9,1447 -1454 
(1990)04FS6L
[Food and Drug 
Administration (CDER) 
2007]Food and Drug Administration (CDER). Guidance for 
Industry : clinical data needed to support the licensure 
of pandemic influenza vaccines. Silver Spring: U.S. 
Department of Health and Human Services; 2007. 17 
p.04GKNY 
  04Y38Y 
  05FQSH
PRODUCT: V114 103
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
[Frenck, R. W. Jr., et al 
2012]Frenck RW Jr, Gurtman A, Rubino J, Smith W, van 
Cleeff M, Jay awardene D, et al. Randomized, 
controlled trial of a 13-valent pneumococcal conjugate 
vaccine administered concomitantly  with an influenza 
vaccine in healthy adults. Clin Vaccine Immunol. 
2012 Aug;19(8):1296 -303.040DGC
[Gilchrist, S. A., et al 
2012]Gilchrist SA, Nanni A, Levine O. Benefits and 
effective ness of administering pneumococcal 
polysaccharide vaccine with seasonal influenza 
vaccine: an approach for policy makers. Am J Public 
Health. 2012 Apr;102(4):596 -605.040DG8
[Grohskopf, L . A., et al 
2015]Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, 
Broder KR, Karron RA. Prevention and Control of 
Influenza with Vaccines: Recommendations of the 
Advisory  Committee on Immunization Practices, 
United States, 2015 -16 Influenza Season. MMWR 
Morb Mortal Wkly  Rep. 2015 Aug 7;64(30):818 -25.04GD09
[Grohskopf, L. A., et al 
2016]Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, 
Karron RA, Jernigan DB, et al. Prevention and control 
of seasonal influenza with vaccines: recommendations 
of the Advisory  Committee on Immunization Practices 
(ACI P) --United States, 2016 -17 influenza season. 
MMWR Morb Mortal Wkly  Rep. August 26, 2016 / 
65(5);1 –54.04NJRS
[Grohskopf, L . A., et al 
2017]Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, 
Bresee JS, Fry  AM, et al. Prevention and control of 
seasonal influenza with vaccines: recomm endations of 
the advisory  committee on immunization practices -
United States, 2017 -18 influenza season. MMWR 
Recomm Rep. 2017 Aug 25;66(2):1 -20.04W72Z
[Guevara, M., et al 
2016]Guevara M, Barricarte A, Torroba L, Herranz M, Gil -
Setas A, Gil F, et al. Di rect, indirect and total effects 
of 13- valent pneumococcal conjugate vaccination on 
invasive pneumococcal disease in children in Navarra, 
Spain, 2001 to 2014: cohort and case -control study . 
Euro Surveill. 2016;21(14).04KSQ3
[Jokinen, J., et al 2015] Jokinen J, Rinta -Kokko H, Siira L , Palmu AA, 
Virtanen MJ, Nohy nek H, et al. I mpact of ten -valent 
pneumococcal conjugate vaccination on invasive 
pneumococcal disease in Finnish children a 
population -based study . PLoS One. 2015 Mar 
17;10(3):e0120290.04KW7F 
  04Y38Y 
  05FQSH
PRODUCT: V114 104
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
[Kobay ashi, M., et al 
2015]Kobay ashi M, Bennett NM, Gierke R, Almendares O, 
Moore MR, Whitney  CG, et al. Intervals Between 
PCV13 and PPSV23 Vaccines: Recommendations of 
the Advisory  Committee on I mmunization Practices 
(ACI P). MMWR Morb Mortal Wkly  Rep. 20 15 Sep 
4;64(34):944 -7.04P7L H
[Kunzel, W., et al 
1996]Kunzel W, Glathe H, Engelmann H, Van Hoecke C. 
Kinetics of humoral antibody response to trivalent 
inactivated split influenza vaccine in subjects 
previously  vaccinated or vaccinated for the first time . 
Vaccine. 1996 Aug;14(12):1108 -10.044JVG
[Lepoutre, A., et al 
2015]Lepoutre A, Varon E, Georges S, Dorleans F, Janoir 
C, Gutmann L , et al. I mpact of the pneumococcal 
conjugate vaccines on invasive pneumococcal disease 
in France, 2001 -2012. Vaccine. 201 5 Jan 3;33(2):359 -
66.04KW88
[Lexau, C. A., et al 
2005]Lexau CA, Ly nfield R, Danila R, Pilishvili T, 
Facklam R, Farley  MM, et al. Changing epidemiology  
of invasive pneumococcal disease among older adults 
in the era of pediatric pneumococcal conjugate 
vaccine. JAMA 2005;294(16):2043 -51.03RBPW
[Liang, K -Y and Zeger, 
S. L. 2000]Liang K -Y, Zeger SL. Longitudinal data anal ysis of 
continuous and discrete responses for pre -post 
designs. Sank yha: The Indian Journal of Statistics 
2000;62(Series B, Part 1):134 -48.00V5V6
[Martinelli, D., et al 
2014]Martinelli D, Pedalino B, Cappelli MG, Caputi G, 
Sallustio A, Fortunato F, et al Towards the 13 -valent 
pneumococcal conjugate universal vaccination: 
effectiveness in the transition era between PCV7 and 
PCV13 in Italy, 2010 -2013. Hum Vaccin I mmunother. 
2014;10(1):33 -9.04KW8B
[Matias, G., et al 2014] Matias G, Tay lor R, Haguinet F, Schuck -Paim C, 
Lustig R, Shinde V. Estimates of mortality  attributable 
to influenza and RSV in the United States during 
1997 -2009 by  influenza ty pe or subty pe, age, cause of 
death, and risk status. Influenza Other Respir Viruses. 
2014 Sep;8(5):507 -15.04NFHW
[Metlay , J. P., et al 
2006]Metlay  JP, Fishman NO, Joffe M, Edelstein PH. 
Impact of pediatric vaccination with pneumococcal 
conju gate vaccine on the risk of bacteremic 
pneumococcal pneumonia in adults. Vaccine 
2006;24:468 -75.03RC46 
  04Y38Y 
  05FQSH
PRODUCT: V114 105
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
[Miettinen, O. and 
Nurminen, M. 1985]Miettinen O, Nurminen M. Comparative Anal ysis of 
Two Rates. Stat Med 1985;4:213 -26.03QCDT
[Moore, M. R., et al 
2015]Moore MR, L ink-Gelles R, Schaffner W, Ly nfield R, 
Lexau C, Bennett NM, et al. Effect of use of 13 -valent 
pneumococcal conjugate vaccine in children on 
invasive pneumococcal disease in children and adults 
in the USA: analy sis of multisite, population -based 
surveillance. Lancet Infect Dis. 2015 Feb 3. [Epub 
ahead of print].043MRP
[Palmu, A. A., et al 
2015]Palmu AA, Kilpi TM, Rinta -Kokko H, Noh ynek H, 
Toropainen M, Nuorti JP, et al. Pneumococcal 
conjugate vaccine and clinically suspected invasive 
pneu mococcal disease. Pediatrics. 2015 
Jul;136(1):e22 -7.04KVRL
[Pilishvili, Tamara, et 
al 2010]Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison 
LH, Bennett NM, et al. Sustained reductions in 
invasive pneumococcal disease in the era of conjugate 
vaccine. J Infect Dis 2010;201(1):32 -41.03R5S4
[Reber, A. 2013] Reber A, Katz J. I mmunological assessment of 
influenza vaccines and immune correlates of 
protection. Expert Rev Vaccines. 2013;12(5):519 -36.04W9TH
[Romero -Steiner, S., et 
al 1997]Romero -Steiner S , Libutti D, Pais LB, Dy kes J, 
Anderson P, Whitin JC, et al. Standardization of an 
opsonophagocy tic assay  for the measurement of 
functional antibody  activity  against streptococcus 
pneumoniae using differentiated HL -60 cells. Clin 
Diagn Lab Immunol 1997;4(4 ):415 -22.03NWQ5
[Ruckinger, S., et al 
2009]Ruckinger S, van der Linden M, Reinert RR, von 
Kries R, Burckhardt F, Siedler A. Reduction in the 
incidence of invasive pneumococcal disease after 
general vaccination with 7 -valent pneumococcal 
conjugate vaccin e in Germany . Vaccine 
2009;27:4136 -41.03QYQQ
[Schwarz, T. F. 2013] Schwarz TF, Schmoele -Thoma B. Assessment of 
functional antibacterial opsonophagocy tic antibodies 
elicited by  13-valent pneumococcal conjugate vaccine 
administered concomitantly  with triva lent influenza 
vaccine in a randomized clinical trial in adults aged 
>=65 years. Vaccine. 2013;31:291 -4.04WR0V 
  04Y38Y 
  05FQSH
PRODUCT: V114 106
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
[Schwarz, T. F., et al 
2011]Schwarz TF, Flamaing J, Rumke HC, Penzes J, 
Juergens C, Wenz A, et al. A randomized, double -
blind trial to evaluate immunogenicit y and safet y of 
13-valent pneumococcal conjugate vaccine given 
concomitantly  with trivalent influenza vaccine in 
adults aged >=65 years. Vaccine. 2011;29:5195 -202.04WQY8
[Song, J. Y., et al 2010] Song JY, Cheong HJ, Hwang IS, Choi W S, Jo YM, 
Park DW, et al. L ong-term immunogenicity  of 
influenza vaccine among the elderl y: Risk factors for 
poor immune response and persistence. Vaccine. 2010 
May 21;28(23):3929 -35.044JVF
[Thompson, W. W., et 
al 2004]Thompson WW, Shay  DK, Weintraub E, Brammer L, 
Bridges CB, Cox NJ, et al. I nfluenza -associated 
hospitalizations in the United States. JAMA. 2004 Sep 
15;292(11):1333 -40.04NFMG
[Tomczy k, S., et al 
2014]Tomczy k S, Bennett NM, Stoecker C, Gierke R, 
Moore MR, Whitney  CG, et al. Use of 13 -valen t 
pneumococcal conjugate vaccine and 23 -valent 
pneumococcal poly saccharide vaccine among adults 
aged is greater than or equal to 65 y ears: 
recommendations of the Advisory Committee on 
Immunization Practices (ACI P). MMWR Morb 
Mortal Wkly  Rep. 2014 Sep 19;63 (37):822 -5.040XNF
[U.S. Department of 
Health & Human 
Services 2018]U.S. Department of Health & Human Services. 
ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. 
National L ibrary  of Medicine. Study  title: 
Concomitant administration of 13 -valent 
pneumoco ccal conjugate vaccine (13vPnC) with 
Influenza vaccine in 23 -valent pneumococcal 
polysaccharide (23vPS) pre -vaccinated adults; [cited 
2018 May  5]; [1 screen]. Available from: 
https://clinicaltrials.gov/ct2/results?pg=1&load=cart&
id=[STUDY_ID_REMOVED].04XDQK
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Administration (CDER, CBER, 
CDRH). Guidance for industry  patient -reported 
outcome measures: use in medical product 
development to support labeling claims [I nternet]. 
Washington: U.S. Department of Health and Human 
Services; 2009. Available from: 
https://www.fda.gov/downloads/drugs/guidances/ucm
193282.pdf04MG9J 
  04Y38Y 
  05FQSH
PRODUCT: V114 107
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
[Wagenvoort, G. H., et 
al 2016]Wagenvoort GH, Knol MJ, de Melker HE, Vlaminckx 
BJ, van der Ende A, Rozenbaum  MH, et al.  Risk and 
outcom es of invasive pneumococcal disease in adults 
with underlying conditions in the post -PCV7 era, The 
Netherlands. Vaccine. 2016 Jan 12;34(3):334 -40.04KTDB
[Waight, P. A., et al 
2015]Waight PA, Andrews NJ, L adhani SN, Sheppard CL , 
Slack MP, Miller E. Effec t of the 13 -valent 
pneumococcal conjugate vaccine on invasive 
pneumococcal disease in England and Wales 4 y ears 
after its introduction: an observational cohort study. 
Lancet Infect Dis. 2015 May ;15(5):535 -43.04KTF2
[Weiss, S., et al 2015] Weiss S, Falken horst G, van der Linden M, Im ohl M, 
von Kries R. I mpact of 10 -  and 13- valent 
pneumococcal conjugate vaccines on incidence of 
invasive pneumococcal disease in children aged under 
16 years in German y, 2009 to 2012. Euro Surveill. 
2015 Mar 12;20(10):21057.04KTFC
[Whitney , Cynthia G., 
et al 2003]Whitney  CG, Farley  MM, Hadler J, Harrison LH, 
Bennett NM, Lynfield R, et al. Decline in invasive 
pneumococcal disease after the introduction of 
protein -polysaccharide conjugate vaccine. N Engl J 
Med 2003;348(18):173 7-46.03QT0D
[WHO Global 
Influenza Surveillance 
Network 2011]WHO Global I nfluenza Surveillance Network. Manual 
for the laboratory  diagnosis and virological 
surveillance of influenza [I nternet]. Geneva (CH): 
World Health Organization; 2011. Available from: 
http://apps.who.int/iris/bitstream/10665/44518/1/9789
241548090_eng.pdf.04HMD6
[Zakay -Rones, Z. 2010] Zakay -Rones Z. Human influenza vaccines and 
assessment of immunogenicity . Expert Rev Vaccines. 
2010;9(12):1423 -39.04W9TB 
  04Y38Y 
  05FQSH
PRODUCT: V114 108
PROTOCOL/AMENDMENT N O.: 021 -01 
V114 -021-01-FINAL PROTOCOL 1-JUN-2018
[Zhang, Y. Y., et al 
2016]Zhang YY, Tang XF, Du CH, Wang BB, Bi ZW, 
Dong BR. Comparison of dual influenza and 
pneumococcal poly saccharide vaccination with 
influenza vaccination alone for preventing pneumonia 
and reducing mortality  among the elderl y: a meta -
analysis. Hum Vaccin I mmunother. 
2016;12(12):3056 -64.04XF37
[Zhou, H., et al 2012] Zhou H, Thompson WW, Viboud CG, Ringholz CM, 
Cheng PY, Steiner C, et al. Hospitalizations associated 
with influenza and respiratory s yncytial virus in the 
United States, 1993 -2008. Clin I nfect Dis. 2012 
May;54(10):1427 -36.04NFHY 
  04Y38Y 
  05FQSH